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ABSTRACT

The goal of this project was to determine the genome organization, replication
strategy and identification o f the large envelope glycoprotein (Gl) gene of simian
hemorrhagic fever virus (SHFV). This virus is the fourth member of the new virus family
Arteriviridae
The 3' end of the RNA genome from the prototype isolate of SHFV was cloned and
sequenced. This 6314 nucleotide (nt) sequence consisted of nine complete overlapping open
reading frame (ORFs 2 ,2a, 3 ,4 ,5 ,6 ,7 ,8 , and 9). At the 5’ end of this sequence is a partial
ORF, ORF lb, and the 3' end is a noncoding region. The sequence data showed that SHFV
encodes three additional ORFs as compared to the other arteriviruses. The nine SHFV 3'
ORFs were presumed to be translated from separate subgenomic mRNAs (sgRNAs)
produced during virus replication. However, RT-PCR analysis using leader- and ORFspecific primers identified only eight sgRNA species. The sequence, 5 '-UCNUUAACC-3',
was identified as the junction motif between the mRNA body and the 5' leader sequence.
An ORF 2b-specific sgRNA was not detected.
The SHFV particle consists of two proteins, pl5 and p20, and at least two
glycoproteins, p42 and p54. Endoglycosidase treatment of purified SHF virions showed that
p42 and p54 were actually four separate peptides with molecular masses between 28 and 30
kDa. Thus, the SHFV particle contains at least six structural proteins. In -vitro synthesis of
the ORF 7 product resulted in a peptide with a molecular mass of 31 kDa; this mass
increased to 52 kDa when the in vitro product was glycosylated.

However, when the

xi
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glycosylated ORF 7 product was treated with endoglycosidase, the molecular weight of the
peptide shifted to about 29,000. Immunoprecipitation results showed that the ORF 7 product
was one of the SHFV GL proteins (p54). Four antigenic epitopes were identified using
monoclonal antibodies generated by genetic immunizations of mice with the ORF 7 gene.
One of these epitopes was identified as a virus neutralization site. The ORF 7 genes from
two additional SHFV isolates were compared to the ORF 7 gene from the prototype isolate.
No sequence difference was observed among these three isolates.

xii
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1.

INTRODUCTION/ LITERATURE REVIEW

1.1 Pathogenesis and transmission o f SHFV.
Simian hemorrhagic fever virus (SHFV) was first isolated in 1964 from diseased
macaque monkeys in a quarantine facility at the National Institute of Health (NIH) after an
epizootic of hemorrhagic fever within the colony. This initial epizootic resulted in the death
o f223 of the 1050 animals in the facility (Palmer, et al., 1968). Concurrent with the NIH
outbreak was a second epizootic at the Sukhumi Institute of Experimental Pathology and
Therapy in the former Soviet Union. The same Indian supplier had shipped monkeys to both
the NIH and Soviet Union facilities (Palmer, et al., 1968; Tauraso, et al., 1968).
Since the discovery of SHFV, many outbreaks have been reported in non-human
primate captive colonies throughout the world. Additional outbreaks have been reported in
macaque facilities in the United States in 1967,1972, and 1989, in Great Britain between
1966 and 1969, and in Italy in 1992 (Plagemann, 1996).
The most recent SHFV outbreaks in the United States occurred in 1989. The first
epizootic in that year was reported in the Primate Research Institute at the New Mexico State
University in Alamorgordo; 400 macaques out of a population of approximately 2,000 died
during this outbreak (Renquist, 1990). Later in that same year, three additional outbreaks
were reported in Virginia, Pennsylvania, and Texas (Jahrling, et al., 1990). All affected
monkeys were imported to these three facilities in the United States from the same Philippine
supplier (Jahrling, et al., 1990). Most, but not all, monkeys involved in these latter
outbreaks were co-infected with a second virus, Reston virus, which is a member of the

1
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genus Filovirus. Until the isolation of Reston virus, all filoviruses were considered highly
lethal in humans. However, similar to SHFV, Reston virus does not appear to cause disease
in humans (Jahrling, et al., 1990). The effect of SHFV on the Reston virus, and vice-versa,
is not known. In 1992, another simultaneous SHFV/ filovirus outbreak was reported in
Sienna, Italy. The monkeys affected were imported from the same Philippine supplier
involved in the late 1989 epizootics in the United States (P. Jahrling, USAMRHD, Fort
Detrick, personal communication).
SHFV induces a fatal hemorrhagic fever in rhesus {Macaco, mulatto), cynomolgus
(Macaca fascicularis), stump-tail (Macaca speciosa), and bonnet (Macaca radiata)
monkeys (Abildgaard, et al., 1975; Palmer, et al., 1968). Therefore, it is believed that all
macaque monkeys are susceptible to SHFV disease. SHF in macaque monkeys progresses
rapidly; macaques which were experimentally infected with SHFV developed clinical
symptoms of disease within 1-2 days and died within 1-2 weeks post-inoculation
(Abildgaard, et al., 1975). In the 1972 outbreak at the NIH facilities, 212 macaques were
lost within a 12 day period (London, 1977). The onset o f the disease in macaques consists
of early fever, mild facial edema, anorexia, adipsia, dehydration, proteinuria, cyanosis,
bloody diarrhea, nose bleeds, and occasional hemorrhages in the skin (Allen, et al., 1968;
London, 1977; Palmer, et al., 1968). Pathological lesions consist of capillary-venous
hemorrhages in many tissues. The lesions are often associated with evidence of vasodilation,
stasis, and venous thrombosis. Thus, shock is suspected as the underlying causative factor
of death (Gravell, et al., 1986a; Gravell, et al., 1986b).
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Although SHFV causes a fatal disease in monkeys within the genus Macaca, this
virus can induce persistent infections in African monkeys such as patas monkeys
(Erythrocebuspatas), African green monkeys (Cercopithecus aethiops), and baboons (Papio
anuibus and Papio cynocephalus) without inducing signs of clinical illness. Since viremia
has been detected in these African monkey species, it was suggested that these species may
be natural hosts for SHFV (Gravell, et al., 1986b; London, 1977). A survey o f patas
monkeys caught in the wild and imported from Africa to the United States indicated that
49% of the 216 animals tested were persistently infected with SHFV as demonstrated by
isolation of the virus from the blood of these monkeys (Gravell, et al., 1980a).
Although most SHFV isolates induce persistent infections in African monkeys
without overt clinical signs, a spectrum of virus variants exist in nature which vary greatly
in virulence for patas monkeys (Gravell, et al., 1986b). The more virulent strains replicate
efficiently in macrophages of these monkeys causing an acute infection which is associated
with high levels of viremia but which is eventually cleared by an effective antiviral immune
response (Gravell, et al., 1986b). In contrast, the replication of the less virulent SHFV
variants seems more restricted in patas monkeys to an as-of-yet unidentified cell type and the
variants seem to be less immunogenic.

Infection with these variants leads to an

asymptomatic persistent infection associated with relatively low levels of viremia and a lack
of formation of neutralizing antibodies (Gravell, et al., 1986a; Gravell, et al., 1986b). In
spite of these differences in virulence in patas monkeys, all variants cause an acute, fatal,
hemorrhagic disease in macaque monkeys (Gravell, et al., 1986a; Gravell, et al., 1986b).
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The mode of transmission of SHFV among African monkeys in the wild is unclear.
No insect vector has been identified. The virus is not transmitted from persistently infected
mothers to their offspring. Infection most likely occurs through open wounds and by biting,
but sexual transmission has not been ruled out (Gravell, et al., 1980b).
No natural epizootics of SHFV in macaque monkeys have been reported. Obviously,
natural transmission of SHFV from persistently infected African monkeys to macaque
monkeys residing in Asia is excluded because o f the geographical separation o f these genera
of monkeys. Usually, SHF disease develops in macaque monkeys shortly after they are
imported to primate facilities from various Asian countries; however, when and how they
become infected is unclear (Jahrling, et al., 1990). In fact, the source o f virus in most of the
past epizootics has not been proved. Because one epizootic had been attributed to injection
of both macaque and African monkeys from a multidose vial with a common needle and
syringe, the current hypothesis is that epizootics of SHF in captive macaque monkey colonies
originates from accidental mechanical transmission o f SHFV from persistently infected
African monkeys (Gravell, et al., 1986a; London, 1977). With respect to the most recent
SHFV epizootics in both the United States and Italy, in which all of the affected monkeys
were shipped from the same Philippine supplier, contact of these macaques with persistently
infected African monkeys either in the Philippines or during transit could not be ruled out
(Jahrling, et al., 1990). In the laboratory, researchers were not able to infect various
laboratory animals such as mice, rats, hamsters, and guinea pigs with SHFV (Tauraso, et al.,
1968). However, this virus was isolated from one mouse trapped during the New Mexico
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epizootic in 1989 (P. Jahrling, personal communication). Therefore, the existence of
alternate hosts as a source of infectious virus needs to be evaluated further.
Once illness becomes apparent, the disease spreads rapidly throughout the macaque
colony. Although the mode of transmission of this virus between macaque monkeys is
unknown, it is believed that SHFV can be spread among these susceptible animals by aerosol
or direct contact (London, 1977).
1.2 SHFV replication in cell culture
All isolates of SHFV replicate in primary rhesus monkey peritoneal macrophage
cultures. Rhesus monkey macrophage cultures are routinely utilized for isolation of new
SHFV isolates. SHFV causes lytic infections in primary macrophage cultures; within three
days after SHFV infection, rhesus monkey macrophages will round-up and lyse (Tauraso,
et al., 1968). In fact, it has been proposed that the severity of cytopathic effect by SHFV on
rhesus monkey macrophages may explain the disease and lethality of this virus in macaque
monkeys (Gravell, et al., 1986b).
Along with primary monkey macrophage cultures, the prototype isolate of SHFV,
LVR 42-0/M6941, will also replicate in the MA-104 (Gravell, et al., 1986a; Gravell, et al.,
1986b; Tauraso, et al., 1968) and the BSC-1 (Tauraso, et al., 1968) cell lines. Both of these
cell lines were derived from African green monkey kidney cells. This SHFV isolate will also
replicate in two other cell lines, CL-2621 and MARC-145 cells, which are subclones o f the
MA-104 cell line (Plagemann and Moennig, 1992). Replication of SHFV in MA-104 cell
cultures is rapid; release of progeny virus begins about 4 h post-infection (p.i.) reaching
maximum titers around 24 h p.i. Cytopathic effects (CPE) become apparent in productively
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infected MA-104 cell cultures at 12-15 hr p.i. CPE begins as foci of highly re tra c tile
spindle-shaped cells which remain connected to each other by long, thin protoplasmic
projections. As the CPE progresses, the cells become rounded and detach from the culture
flask (Tauraso, et al., 1968). The CPE induced by the prototype isolate of SHFV on MA-104
cells allows for the titration of this virus by the plaque assay method. Virus yields in
infected cultures routinely reach 106 to 107plaque-forming units/ml of culture fluid. Neither
interferon production nor defective interfering particles were detected in infected MA-104
cell cultures (Gravell, et al., 1980b). Interestingly, SHFV does not induce CPE in BSC-1
cells. These cells continue to release virus without overt cytopathology (Tauraso, et al.,
1968).
13 Classification
Based on morphological characteristics, SHFV was initially classified within the
virus family Togaviridae (Trousdale, et al., 1975). These characteristics include (1) an
icosahedral nucleocapsid with a diameter of 25 nm, (2) a viral envelope surrounding the
nucleocapsid conferring the entire virus particle a diameter of 50-60 nm, and (3) the lack of
noticeable spike proteins protruding from the surface of the virion (Trousdale, et al., 1975).
In 1985, the family Togaviridae was divided into two virus families, Togaviridae and
Flaviviridae (Westaway, et al., 1985). Although morphologically similar, the togaviruses
and flaviviruses differ in replication strategies, genome characteristics and organizations, and
the membrane types used for budding from the host cell. Because it was thought that SHFV
buds through the endoplasmic reticular membrane instead of the plasma membrane, as do
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the togaviruses, SHFV was removed from the family Togaviridae and reclassified as an
unclassified member of the virus family Flaviviridae (Westaway, et al., 1985).
During the late 1980's and early 1990's, many viral genomes were being sequenced.
Based on sequence data, it was determined that many viruses previously thought to be
unrelated were genetically similar. As a result of genetic analyses and sequence data, the
International Committee on the Taxonomy of Viruses (ICTV) created a new, free-standing
genus Arteriviruses (Cavanagh, et al., 1994). This virus genus included equine arteritis virus
(EAV), lactate dehydrogenase-elevating virus (LDV), porcine reproductive and respiratory
syndrome virus (PRRSV), and SHFV. Most recently, the ICTV created a new virus order,
Nidovirales which includes the families Arteriviridae and Coronaviridae (de Vries, et al.,
1997). The Arteriviridae is a monogeneric family containing the genus Arterivirus, while
the bigeneric virus family Coronaviridae includes the genera Coronavirus and Torovirus.
These two families within this virus order share similar genome organizations and replication
strategies, although morphologically they are very different (de Vries, et al., 1997).
Aside from the physical properties, the arteriviruses share many common
characteristics (reviewed in Plagemann and Moennig, 1992). First, all o f these viruses
establish asymptomatic, persistent infections in their natural hosts. Second, the replication
cycles of all the arteriviruses are very similar and rapid. Third, macrophages are the primary
target cell of these viruses in their natural hosts. This fact has been most clearly established
for LDV. In the case of EAV, PRRSV, and SHFV it has not been resolved whether other
types of cells in their respective hosts may also become productively infected. The
replication of LDV and SHFV in vitro is highly restricted to primary macrophage cultures,
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except for the tissue culture adapted, prototype SHFV isolate. EAV is the most promiscuous
of the arteriviruses in that it will replicate in many different cell lines, ie. VERO, BHK, and
MA-104 cells.
1.4 Physical characteristics of SHFV
SHFV has been shown to be enveloped, pH sensitive, and relatively heat stable
(Tauraso, et al., 1968). The virion particle is spherical with a diameter o f50-60 nm with a
nucleocapsid diameter of 25 nm (Trousdale, et al., 1975). The sedimentation coefficient of
the virion particles is 214 S while that of the nucleocapsid is 174 S (Sagripanti, 1984). The
prototype SHFV isolate exhibits a buoyant density in sucrose density gradients of about 1.15
g/cm3and 1.18 g/cm3in sodium-tartrate gradients (Trousdale, et al., 1975). The virus does
not agglutinate erythrocytes of mice, rats, hamsters, guinea pigs, or chickens. No serological
cross-reaction between SHFV and other arteriviruses has been detected (Plagemann and
Moennig, 1992).
1.5 Arteriviral structural proteins
Viral structural proteins are proteins found in/on the mature virion particle. The
structural proteins of EAV, LDV and PRRSV are similar in number and type. Arteriviruses
generally contain a basic nucleocapsid protein (N) which forms the icosahedral capsid shell
surrounding the viral genome, a nonglycosylated triple-spanning membrane protein (M) and
one to two glycoproteins found embedded within the viral envelope (Gx, B, or Vp3). The
glycoproteins generally smear into broad bands during separation by polyacrylamide gel
electrophoresis (PAGE). The EAV particle contains at least two proteins and two
glycoproteins: a 14 kD phosphorylated N protein; a 16 kDa M protein; Gs, which is a 25 kDa
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glycosylated envelope protein; and GL, a second glycosylated envelope protein between 30
and 42 kDa (de Vries, et al., 1992). PRRSV contains a 15 kDa N protein, an 18 kDa M
protein, and a 25 kDa glycosylated envelope protein (E) (Meulenberg, et al., 1995). The
LDV particle is known to contain at least three structural proteins: Vpl, a 15 kDa N protein;
Vp2, an 18 kDa M protein; and Vp3, a 24 to 44 kDa envelope glycoprotein.
The arteriviral envelope glycoproteins most probably represent the virus attachment
protein because they are found in abundance on the outer surface of the viral envelope and
neutralizing antigenic epitopes can be mapped to these proteins (reviewed in Plagemann,
1996).

The antibodies that neutralize EAV infectivity are all specific for the GL

glycoprotein. In fact, six neutralizing monoclonal antibodies to EAV recognize a single
epitope in the ectodomain of GL (Balasuriya, et al., 1995b). Similarly, several anti-LDV
neutralizing monoclonal antibodies recognize the envelope glycoprotein (VP-3) of LDV
(Faaberg and Plagemann, 1995).
Unlike the other arteriviruses, the number of structural proteins within the SHFV
particles has been controversial for some years. Electropherograms by Trousdale, et al.
(1975) suggested that the SHF virion consists of four structural proteins and two
glycoproteins. These investigators did not report on the molecular weights of these proteins.
Leon, et al. (1982) reported that the viral particle consists of four structural proteins with
molecular masses of 10,12,16, and 25 kDa and a structural glycoprotein o f 50 kDa; these
results were obtained by SDS-PAGE and immunoprecipitation studies. A decade later, the
same group found only three structural proteins within the SHF virion: a 12 kDa
nucleocapsid protein (N or VP-1), a 16 to 18 kDa non-glycosylated envelope protein (M or
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VP2), and an envelope glycoprotein (E or VP-3) of about 50 kDa (Plagemann and Moennig,
1992; Leon-Monzon, unpublished data). Most recently, Godeny, et al. (1995) determined
the size and number of SHFV structural proteins. Four SHFV structural proteins were
identified with apparent molecular masses of 15 (pl5), 20 (p20), 38-46 (p42) and 48-60
(p54) kDa, as measured by SDS-PAGE analysis. pl5 was identified as the capsid (N)
protein and the other three proteins were associated with the viral envelope. p20 was
identified as the nonglycosylated membrane protein (M). The p42 (Gg) and p54 (Gl) bands
represented glycoproteins which ran as smears by SDS-PAGE (Godeny, et al., 1995). It was
not known whether these broad glycoprotein bands each represented one glycoprotein with
different amount of glycosylation or different similar molecular weight glycoproteins which
co-migrated.
1.6 Genomic characteristics of the arterivirnses
The arteriviruses are morphological similar to the togaviruses. However, in genome
organization and replication strategy, these viruses are more similar to the coronaviruses
(reviewed in Snijder and Spaan, 1995; de Vries, et al., 1997; Snijder and Meulenberg, 1998).
The genomes of EAV, LDV and PRRSV have been sequenced and were shown to be 12.7
kb (den Boon, et al., 1991a), 14.2 kb (Godeny, et al., 1993) and 15.1 kb (Meulenberg, et al.,
1993b) in length, respectively. The genomes of these viruses encode eight open reading
frames (ORFs), designated ORFs la, lb, 2,3,4 ,5 ,6 and 7 (Fig. 1) according to conventional
nomenclature (Cavanagh, et al., 1990).
The 5' terminal two-thirds of the viral genomes are taken up b y two large ORFs, la
and lb . The products of these ORFs are translated from the frill length genome RNA. The
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translation of ORF lb, which is in a -1 reading frame relative to ORF la, requires a
ribosomal frameshift immediately before ORF la termination (den Boon, et al., 1991a). This
frameshift event occurs because of the presence of a “slippery sequence”, the actual
frameshift site, and a downstream RNA pseudoknot structure at the ORFs la-lb junction
(den Boon, et al., 1991a). Although these frameshift signals have been identified within the
EAV (den Boon, et al., 1991a), LDV (Godeny, et al., 1993) and PRRSV (Meulenberg, et al.,
1993b) genomes, the functionality of these signals has only been demonstrated for EAV (den
Boon, et al., 1991a). ORFs la and lb encode polyproteins which are post-translationally
cleaved into the viral nonstructural proteins, ie. the viral polymerase, proteases and other
proteins necessary for viral replication. Four highly conserved peptide domains are found
within the ORF lb gene (Fig. 1); these domains are conserved among all members of the
virus order Nidovirales (de Vries, et al., 1997). The first domain, Domain 1, encodes the
viral polymerase motif. Although most viral RNA-dependent RNA polymerases contain the
typical -GDD- amino acid sequence, members of the order Nidovirales possess an -SDDsequence (de Vries, et al., 1997). Domain 2 contains a metal binding protein motif and
domain 3 is a helicase motif. Domain 4, also known as the carboxy terminal domain,
encodes a peptide motif which is only found in viruses within the order Nidovirales. The
function of domain 4 remains undetermined but has been postulated to play a role in
subgenomic mRNA synthesis (den Boon, et al., 1991a).
The remaining one-third o f the arteriviral genomes, downstream of ORF lb, encodes
ORFs 2 through 7 (Fig. 1) which usually overlap their respective adjacent 5' ORFs. Using
the EAV terminology, ORFs 2, 5, 6 and 7 of EAV, LDV and PRRSV encode the small
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Figure 1: Schematic representation of the genome organization (A) and replication
strategy (B) of EAV, the prototype arterivirus. All ORFs and sgRNAs are drawn
approximately to scale. The ORFs are numbered la through 7 and the sgRNAs are
numbered RNA 1 through 7. The locations of the conserved domains in ORF lb are
shown in black and are labeled d l (replicase), d2 (metal-binding), d3 (helicase), and d4
(carboxy-terminal).
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envelope glycoprotein (Gg), the large envelope glycoprotein (G [), the membrane protein (M)
and the nucleocapsid protein (N) (de Vries, et al., 1992; Faaberg and Plagemann, 1995;
Godeny, et al., 1990; Mardassi, et al., 1996; Meulenberg and Petersen-den Besten, 1996;
Meulenberg, et al., 1995).

It has been reported that ORFs 3 and 4 of PRRSV encode

additional viral structural glycoproteins (vanNieuwstadt, et al., 1996). However, the LDV
ORF 3 and EAV ORF 4 products have not been detected in purified virus particles (de Vries,
et al., 1997; Faaberg and Plagemann, 1997).
The SHFV genome is composed of a 49 S (5.5 X 106 Da) single-stranded RNA
molecule estimated to be approximately 15,000 nucleotides (nt) in length (Sagripanti, 1984).
The genome exhibits positive polarity and is polyadenylated at the 3' terminus (Sagripanti,
1985). A type I cap, m7G(5')ppp(5')Am, is found at the 5' terminal end of the viral genome
(Sagripanti, et al., 1986). The first 954 nt sequence located at the 3' end of the SHFV
genome was reported previously (Godeny, et al., 1995). This sequence included a 76 nt 3'
noncoding region and contained one partial and two complete ORFs. Both of the complete
ORFs overlapped their adjacent 5' ORFs (Godeny, et al., 1995). Similar to the other
arteriviruses, the SHFV N protein mapped to the ultimate 3' ORF and the M protein mapped
to the penultimate ORF (Godeny, et al., 1995).
1.7 Arteriviral subgenomic mRNAs
As discussed above, the EAV, LDV and PRRSV ORFs la and lb products are
translated from genome-length, viral mRNA. The remaining 3' ORFs are translated from
a set of six to seven subgenomic mRNAs (sgRNAs) which are produced during virus
replication. These sgRNAs are co-terminal and nested at the 3' terminal end o f the genome
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(Fig. 1) (Kuo, et al., 1992; Meulenberg, et al., 1993b; van Berio, et al., 1982). Although
most of the sgRNAs are polycistronic, only the 5'-most ORF is translated from each sgRNA.
Each of the sgRNAs is polyadenylated at the 3 ' end and contains a 5' leader sequence (Kuo,
etal., 1992; Meulenberg, etal., 1993b; van Berio, etal., 1982). The leader sequences, which
are approximately 200 nts in length and are encoded at the 5' terminus o f the viral genome,
are thought to be added to each sgRNA by a leader-priming mechanism (Snijder and
Meulenberg, 1998). The 5' leader sequence is joined to the sgRNAs at junction or intergenic
sequences (Snijder and Meulenberg, 1998; Snijder and Spaan, 1995). These junction
sequences are highly conserved among the sgRNAs of a specific virus and are similar among
all of the arteriviruses sequenced to date. The junction sequences have been identified as 5'
-UCAAC(U/C> 3' for EAV (den Boon, et al., 1996), 5' -U(A/G)(U/A)AACC- 3' for LDV
(Godeny, etal., 1993; Kuo,etal., 1992), and5' -GNUNAACC- 3' for PRRSV (Conzelmann,
et al., 1993; Meulenberg, et al., 1993a).
Six sgRNAs have been detected during SHFV replication by Northern blot analyses
(Godeny, et al., 1995; Zeng, et al., 1995). These polyadenylated SHFV sgRNAs (Zeng, et
al., 1995) were shown to be approximately the same length as the sgRNAs of other
arteriviruses (Godeny, et al., 1995). Each of the SHFV sgRNAs was shown to contain a 202
nt, noncoding, 5' leader sequence derived from the 5' end of the viral genome (Zeng, et al.,
1995). Similar to the other arteriviruses, the junction sequence between the 5' leader
sequence and the sgRNA body was determined as 5' -U(C/U)AACC- 3' for the two smallest
SHFV sgRNAs, RNAs 6 and 7 (Zeng, et al., 1995).
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1.8 Overview of the dissertation
Because tittle is known about the molecular characteristics of SHFV as compared to
the other arteriviruses, the main thrust o f this project is to characterize the virion particle.
Emphasis is placed on determining the number of glycoproteins in the viral envelope,
sequencing the SHFV structural protein ORFs, mapping the large envelope glycoprotein on
the viral genome, and evaluating the number of antigenic epitopes on that glycoprotein. The
sgRNA junction sequences are also determined.
The arteriviruses are emerging viruses. Although they have only been identified in
four host species, other animal species, including humans, may harbor unidentified
arteriviruses. EAV and PRRSV are important pathogens to the horse racing and pork
producing industries, respectively, leading to great economic losses. Much effort and
expense is currently being applied to controlling these virus infections. The data generated
from this project could be used for the diagnosis and prevention o f SHFV in primate
colonies. Further, some of this data might also be extrapolated to the other related
arteriviruses and aid in our understanding of their replication processes.
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2.

MATERIALS AND METHODS

2.1 Cell culture and media
MA-104 cells (African green monkey kidney cells) were obtained from Whittaker
Bioproducts, Inc. (Walkersville, MD) and Hela cells (Human epithelioid carcinoma cells)
were obtained from Dr. C.J. Gauntt (University of Texas, Health Science Center, San
Antonio, TX). These cells were cultured in complete minimal essential medium (MEM)
supplemented with 0.056% NaHC03(Gibco BRL, Gaithersburg, MD), 2 mM L-glutamine
(Sigma Chemical Co., S t Louis, Mo), 50 fzg/ml o f gentamycin sulfate (Gibco BRL), and
with 2% fetal calf serum (FCS; Sigma Chemical Co.) in a 5% C02 humidified environment
at 37°C. Upon confluency, cells lines were washed once using phosphate-buffered saline
(PBS, pH 7.4) and treated with 0.025% trypsin in versene salts (Sigma Chemical Co.) to
detach cells. After all the cells detached from the tissue culture flask, they were diluted with
the above medium, and used to seed additional tissue culture flasks (175 cm2) with
approximately 5 x 106cells. Stocks of these cell lines were pelleted at 1000 rpm for 5 min,
resuspended in the FCS with 10% DMSO at a concentration of 5 X 106 cells/ml and frozen
in a KRYO-10 cell freezer (Planar Biomed Products LTD., Sunbury-On-Thames, England)
as directed by the manufacturer. Frozen cell stocks were stored in liquid N2 until needed.
The mouse myeloma cell line, P3x63Ag8.653 (X63 cells), were obtained from Dr.
R. Truax (Cell and Organ Culture Laboratory, School of Veterinary Medicine, Louisiana
State University). The X63 cells were cultured in complete RPMI-1640 media (RPMI;
Gibco BRL) supplemented with 10% FCS, 50 //g/ml gentamycin sulfate, 2 mM L-glutamine
17
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and 10% FCS. Fifteen /zg///l 8-azagnanine (Sigma Chemical Co.) was added to the media
to prevent the cells from reverting from hypoxanthine-guanine phosphoribosyl transferase
(HGPRT)-negative to HGPRT-positive cells. The X63 cells were maintained in a log phase
by passing the cells every three days. Three days prior to cell fusion, the cells were passaged
in the above medium without 8-azaguanine in order to remove residual drug from the
cytoplasmic pool.
Primary monkey macrophages were prepared from rhesus monkey blood which was
obtained from the Tulane Regional Primate Research Center (Covington, LA). Whole blood
was centrifuged at 800 X G for 15 min and the plasma layer was aspirated off. The bufiy
coat was transferred into a new tube and mixed with cold PBS. The mixture was then layered
atop Histopaque (Sigma Chemical Co.) and centrifuged at 800 X G for 40 min. The cells at
the PBS-Histopaque interface were transferred into a fresh tube and washed three times with
cold PBS by centrifugation at 800 X G for 10 min. After washing, the pellet was
resuspended in RPMI medium without FCS and transferred into tissue culture flasks. The
macrophages were attached to the flasks by incubation at 37°C for 6 hr with shaking every
30 min. Then the attached macrophages were washed with RPMI medium without FCS
three times and incubated in complete RPMI medium containing 500 U/ml recombinant
human macrophage-colony stimulating factor (rM-CSF; Cellular Products Inc., Buffalo, NY).
2.2 Viruses
The prototype SHFV isolate (LVR 42-0/M6941) was obtained from the American
Type Culture Collection (ATCC, Rockville, MD). Virus was adsorbed to MA104 cells at
a multiplicity of infection (MOI) o f 0.1 plaque forming units (PFU)/cell for 45 minutes at
room temperature. The cells were then washed and incubated in complete MEM containing
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2% FCS. The supernatant fluid was harvested after 48 hr in a 5% COj, humidified incubator
at 37°C and clarified by centrifugation at 2,000 rpm for 5 minutes followed by a second
centrifugation at 10,000 rpm for 20 minutes. For stock virus, the clarified supernatant fluid
was aliquoted, frozen, and stored at -70°C until needed.
Two other isolates of SHFV, 1-621 and Ph0080, were obtained from Dr. P. Jahrling
(USAMRHD). These isolates were obtained from the 1989 epizootic in New Mexico. 1-621
was isolated from the liver o f a monkey after it was experimentally inoculated with a liver
homogenate from a mouse trapped during the outbreak. Ph0080 was a splenic homogenate
from an infected rhesus monkey. These isolates were cultured in primary monkey
macrophages in RPMI media using the same procedure as described above for the prototype
SHFV isolate in MAI04 cells..
When purified SHFV was needed, the following procedure was used. The viruscontaining supernatant fluid was harvested 48 hr p.i. from infected MA104 cells and clarified
as above. The virus was concentrated by precipitation with 8% polyethylene glycol (PEG
8000; Sigma Chemical Co.). After pelleting by centrifugation at 10,000 rpm for 30 min at
4°C, the virus was resuspended in TN buffer (10 mM Tris-HCl and 50 mM NaCl, pH 7.6)
and centrifuged through a 0.5 M to 2.0 M continuous sucrose gradient in TN buffer at 24,500
rpm for 16 hr. Gradient fractions were collected using an Isco fractionator (Isco Inc.,
Lincoln, Nebraska). Peak fractions containing the virus were pelleted by centrifugation of
30,000 rpm at 4°C for 2 hr.
Virus titers were obtained by the standard plaque assay method (Hierholzer and
Killington, 1996) using MA104 cells. Ten-fold dilutions o f the virus were attached to
MA104 cell monolayers in the 12-well tissue culture plate (Costar Corp., Cambridge, MA)
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for 45 min. The liquid was then removed and the cells were overlaid with nutrient medium
which consisted of complete MEM containing 2% fetal calf serum and 1% low melt agarose
(Amresco Inc., Solon, Ohio). After 36 hr at 37°C in a 5% COz hum idified chamber, the
overlay medium was stained with neutral red dye (Sigma Chemical Co.) for 4-8 hr, and the
virus plaques were counted. All plaque titrations were done in duplicate and were reported
in plaque-forming units per ml (PFU/ ml).
35S-Iabeled viral proteins were prepared by metabolic-radiolabeling of SHFV
particles. Two hours p.i., the MAI04 growth media was replaced with complete MEM
lacking cysteine and methionine and containing only 2% fetal bovine serum. One hour later,
the medium was supplemented with 80 uCi/ ml 3SS- translabel cysteine and methionine/ ml
(ICN, Irvine, CA). Radiolabelled virus particles were purified as described above. For 35Slabeled SHFV cell lysates, the infected cells were washed two times with PBS at 16 hr p.i.
and lysed with lysis buffer containing 50 mM sodium phosphate (pH 8.0), 0.5% (w/v)
sodium deoxycholate, 1% (v/v) Nonidet-P40 (NP-40), 10 mM EDTA, and lug/ ml each of
leupeptin, aprotonin, and pepstatin A (Sigma Chemical Co.).
Viral proteins were also metabolically radiolabeled with l4C-amino acids and3H¥

myristic acid and viral RNA was radiolabeled with 3H-uridine as described above. However,
for I4C radiolabeling, the virus growth medium was replaced with complete MEM with onetenth amino acids containing 2% FCS and 20 uCi/ ml l4C-amino acid mixture (Amersham
Life Science, Inc., Arlington Heights, EL) at 3 hr p.i. For 3H-myristic acid labeling, virus
growth medium was replaced with complete MEM containing 2% FCS and 100 pCi/ ml
[9,10(n)-3H] myristic acid (Amersham Life Science, Inc.) at 3 hr p.i. The SHFV genomic
RNA was also metabolically radiolabeled in MA104 cells. SHFV was grown in these cells
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as described above except that SO ^Ci/mi [5,6-3H] uridine (Amersham Life Science, Inc.)
was added to the media at 3 hr p i. Regardless o f isotope used, all radiolabeled SHFV was
purified as described above.
2 3 Neutralization assay
The standard virus neutralization assay (Chemesky, 1996) was performed with some
modifications. Briefly, serial dilutions of anti-SHFV sera, which had been heat-inactivated
at 56°C for 30 min to inactivate serum complement, was mixed with equal volumes of
SHFV at 103 PFU/ ml. The mixture was incubated at 37°C for 30 min to allow the
antibodies in the sera to attach to the virus particles. Then, the mixture was added to
confluent MAI 04 cell monolayers in 12-well tissue culture plates at 50 PFU/ ml and the
virus was allowed to attach to the cells. The standard plaque assay procedure as described
above was then followed. Plaque numbers in wells containing the virus-antisera mixtures
were compared to those in wells containing virus only; a 50% reduction in plaque number
was considered positive for virus neutralization.
2.4 Viral RNA isolation
The viral RNA was isolated from purified virus particles using the RNase TM Total
RNA Kit (Qiagen, Inc., Chatsworth, CA) as instructed by the manufacture. The RNA
samples were ethanol precipitated and stored at -70 °C until needed. For intracellular RNA
isolation, MA104 cells were infected with the prototype isolate of SHFV, the infected cells
were lysed with lysis buffer at 20 hr p.i. and the intracellular RNA was isolated using the
RNase TM Total RNA K it
Special precautions were taken to prevent RNase digestion of viral RNA during the
isolation procedures and use (Sambrook, et al., 1989). All glassware used in RNA

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

22

experiments was baked at 200°C for 6 hr prior to use. RNA solutions were treated with 0.5
m l/1diethyl pyrocarbonate (DEPC) overnight prior to autoclaving. RNA concentrations were
determined by optical density using a Du 60 Spectrophotometer (Beckman Inc., Palo Alto,
CA).
2.5 Cloning of the 3 ' end of the SHFV genomic RNA
The 3' end of the SHFV RNA genome was cloned as previously described (Godeny,
et al., 1995). A synthetic oligonucleotide DNA primer was synthesized in Gene Lab at the
School of Veterinary Medicine, Louisiana State University and annealed to purified genome
RNA from the prototype isolate of SHFV in 10 mM Tris, pH 7.2,16 mM KC1 at 100°C for
3 m in. The primer sequence, 5'-CCCTTCCATTGAGTATG-3', is complementary to
nucleotides 449- 465 from the 3' terminus of the SHFV genome (Godeny, et al., 1995). The
annealing mixture was slow-cooled (more than 30 min) to room temperature prior to the
addition of 20 mM Tris, pH 8.3, 16 mM KC1, 3.2 mM MgCl2, 80 /zM of each o f the four
deoxynucleotides and 0.17 mM dithiothreitol (DTT). For detection purposes, 20 /j.Ci of
deoxyadenosine 5'-[a-32P] triphosphate (dATP; Amersham Life Science Corp.) was added
to the reaction mixture. Avian myeloblastosis virus (AMV) reverse transcriptase (25 U;
Pharmacia Biotech Inc., Piscataway, NJ) was added to the reaction mixture to synthesize
cDNA copies of the viral RNA at 42°C. After 1 hr, the RNA was phenofrchloroform
extracted and ethanol precipitated.
The second cDNA strand was synthesized at 12°C in a reaction mixture containing
20 mM Tris, pH 7.5,5 mM MgCl2, 10 mM NH4(S04)2, 10 mM KC1,200 /zM o f each o f the
four dNTPs, 5 U £ coli DNA polymerase I, 1 U RNase H and 2 U T4 DNA ligase.
Following a 1 hr incubation, the temperature was increased to 22°C for an additional hour.
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The mixture was heated to 70°C for 1 min, 5 U T4 polymerase was added, and further
incubated for 20 min at 37°C. The reaction was stopped by the addition of 0.25 M EDTA.
The cDNA was phenohchloroform extracted twice and precipitated with ethanol. The
precipitates were resuspended in water and the EcoRI sites within the SHFV DNAs were
methylated using 6 pM S-adenosyl methionine and 2 U EcoRI methylase (New England
Biolabs, Inc., Beverly, MA) in the supplied buffer, overnight at 37°C. The methylated DNA
was then phenohchloroform extracted twice, ethanol-precipitated, and pelleted. Next, 5'phosphorylated EcoRI linkers (Pharmacia Biotech) were added to both ends of the double
stranded DNA at 14°C for 5 hr with T4 DNA ligase (New England Biolabs, Inc.) in ligase
buffer which was supplied by the manufacture. The ligated cDNA was heated to 100°C for
10 seconds and the linkers were then digested overnight with 120 U of restriction
endonuclease EcoRI (New England Biolabs, Inc.) in the buffer supplied by the manufacture
at 37°C. The cDNA was fractionated on a Sepharose 4B column (S igm a Chemical Co.) in
0.2 M Tris, pH 7.4, 0.1 mM EDTA to remove free nucleotides and small oligonucleotide
fragments (<200 nt in length). Fractions from the column were collected and counted in a
beta scintillation counter. Fractions containing peak levels of incorporated radioactivity were
pooled and ethanol-precipitated.
The pelleted cDNA was inserted into the EcoRI-digested pGEM7ZF+plasmid vector
(Promega Corp. Madison, WI) according to the manufacturers instructions by incubating at
room temperature overnight with 4 U T4 DNA ligase and ligase buffer. The recombinant
plasmids were extracted with phenohchloroform and ethanol-precipitated. The DNA pellet
was washed with 70% ethanol and resuspended in water.
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E.coli strain, JM109 (Promega Corp), in exponential growth phase, was pelleted,
resuspended in TFB (10 mM 2-[N-morphoIino]ethanesulfonic acid, 45 mM MnClj, 100 mM
KC1 and 3 mM hexamminecobolt chloride), and treated on ice with 0.33% (v/v) DMSO and
30 mM DTT prior to transformation. The recombinant pGEM plasmids were added to the
treated bacterial cells. The cells were chilled on ice for 30 min, heat-shocked at 42 °C for 90
seconds and then again chilled on ice for 2 min. SOC medium (2% tryptone, 0.5% yeast
extract, 10 mM NaCI, 2.5 mM KC1,10 mM MgCl^, and 20 mM glucose) was added and the
cells were incubated for 1 hr at 37°C on a shaker (220 rpm). The cells were next pelleted
at 1600 rpm for 10 min, resuspended in SOC media and plated on LB agar plates (1%
tryptone, 0.5% yeast extract, 1% NaCI, pH 7.0, 1.5% agar) (Sambrook, et al., 1989)
containing 50 ^ig/ml ampicillin, 5 fxg/1 IPTG and 0.33 mM X-gal. Bacterial plates were
incubated at 37°C overnight. Plasmid-transformed E. coli containing the cloned SHFV
cDNA were screened for p-galactosidase gene expression (Close, et al., 1983). White
colonies were picked, amplified in LB broth containing 50 //g/ml of ampicillin and frozen
at -70°C until screened for SHFV specificity.
The DNA clones were screened for SHFV specificity by Northern blot analysis
(Krumlauf, 1996) using riboprobes (Sambrook, et al., 1989). Riboprobes were synthesized
in vitro using a previously isolated SHFV clone, dt-9. The dt-9 clone contained the first 806
nt from the 3' terminus of the SHFV genome inserted into the pGEM plasmid vector
(Godeny, et al., 1995). The plasmid DNA was extracted from E. coli using the Quantum
Prep Plasmid Miniprep Kit (Bio-Rad Laboratories, Hercules, CA) and cut with the restriction
endonuclease Hind HI (New England BioLabs, Inc.) overnight at 37°C. The linearized DNA
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was extracted with phenolxhloroform. After ethanol precipitation, the DNA was washed in
70% ethanol, dried, and resuspended in water containing 4 U RNasin/^1 (Promega Corp.).
The radiolabelled riboprobes were prepared using the Riboprobe System-T7 kit
(Promega Corp.). Briefly, the DNA was denatured at 70°C for 10 min and then kept on ice.
1 (j.%of this sample was mixed with 80 mM Tris (pH 7.5), 12 mM MgCl2, 10 mM DTT, 80
U RNasin, 10 /xM UTP, 0.5 mM each of ATP, CTP, GTP, 20 U T7 RNA polymerase, and
50 /zCi [a- 32P] uridine triphosphate (Amersham Life Science, Inc.). The reaction was
incubated at 37°C for 90 min and then 1 /xg of RNase-free DNase was added to the mixture
and incubated for an additional 15 min. The probe was extracted with phenolxhloroform
and precipitated with ethanol. The pelleted probe was resuspended in 100 /xl 2.5 mM
piperazine-N,N' -bis[2-ethanesulfonic acid], pH 6.4 (PIPES; Sigma Chemical Co.) and
counted in a scintillation counter.
The DNA clones to be screened were extracted from amplified colonies of E. coli in
LB broth using the Quantum Prep Plasmid Miniprep K it Portions of the minipreps were
mixed with 10X SSC (1.5 M NaCI, 0.15 M Na citrate, pH 7.0), denatured by heating to
100°C for 10 min, and blotted onto a nitrocellulose membrane (Bio-Rad Laboratories,
Hercules, CA), The membrane was air-dried, baked at 80 °C for 2 hr, and then stored at room
temperature until needed.
The dotted DNA membrane was rinsed in DEP-treated water and incubated with
hybridization solution consisting of 50% formamide, 5X Denhardt's solution (0.1% bovine
serum albumin (BSA), 0.1% (w/v) ficoll, 0.1% (w/v) polyvinylpyrrolidine (Sigma Chemical
Co.)), 5X SSPE (0.9 M NaCI, 20 mM sodium phosphate, pH 6.8, and 5 mM EDTA), 0.1%
SDS, 200 /xg! ml salmon sperm DNA, and 200 fxgf ml tRNA. The membrane was
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prehybridized for 4 hr at 45 °C. The RNA probe (105 cpm) was then added to the
hybridization mixture and incubation was continued overnight at 65 °C. The membrane was
washed at room temperature for 20 min in IX SSC and 0.1% SDS followed by three washes
in 0.2X SSC and 0.1% SDS at 68°C for 20 min each. Specific SHFV blots were visualized
by autoradiography.
2.6 Nucleotide sequencing
Minipreps of the plasmid DNA containing the desired SHFV insertions were made
using the Quantum Prep Plasmid Miniprep K it The SHFV cDNAs were sequenced by the
dideoxy chain termination method(Sanger, et al., 1977) using Sequenase® (T7 Polymerase)
supplied in the Sequenase™ Version 2.0 DNA Sequencing Kit (United States Biochemical
Corp., Cleveland, OH). Synthetic oligonucleotides, either homologous to the M l 3-reverse
sequence site or complementary to the M13-universal sequence site on the plasmid vector
were used to prime the DNA templates. Separate sequencing reactions were initiated from
each end of the DNA insert, but on different DNA strands, until an overlapping
complementary sequence was obtained. For long SHFV clones (more than 600 nt), synthetic
oligonucleotide primers (Gene Lab) complementary to a selected 18 to 24 nt region, were
used to prime internal initiation sequencing reactions to "walk along" the entire sequence.
In order to produce the majority sequence of the viral genome, multiple clones for each
nucleotide were sequenced. If more than one clone was not available for a particular
nucleotide, then the nucleotide was determined by direct sequencing of the SHFV RNA
genome.
Viral RNA was sequenced directly by a modified dideoxy chain termination method
(Sleigh, et al., 1981; Wunner, et al., 1985) using the RT- RNA Sequencing Kit according to
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the manufacturers instructions (U.S. Biochemical Corp.).

Briefly, the synthetic

oligonucleotide primer of choice (0.4 f-ig/ /d) was annealed to the viral RNA at 90°C for 1
min in hybridization buffer (20 mM Tris, pH 7.5,10 mM MgCl2, 10 mM NaCI and 0.2 mM
DTT) with 40 U RNasin (Promega Corp) and then placed in a 40 °C water bath for 5 min.
The annealed RNA template reverse-transcribed in hybridization buffer containing 1.4 /ug
actinomycin D, 10 /zM each of dGTP, dTTP, dCTP, 1 fjM dATP, 10 pCi 32P-dATP and 1.5
U reverse transcriptase at 40°C for 5 min. Chain termination occurred when the reaction
mixture was aliquoted into each of the four termination mixes. Each o f the dideoxy ATP,
dideoxy CTP, dideoxy GTP and dideoxy T IP termination mixes contained 0.1 mM of the
respective dNTP and 1 mM of the remaining three dNTPs. The mixes also contained 0.35
mM of the respective dideoxy NTP. Termination reactions were incubated at 39°C for 30
min, after which, the stop solution (10% glycerol, 55% deionized formamide in 2.5X TBE
(45 mM Tris-borate, 1 mM EDTA) containing 0.5% brom phenol blue and 0.5% xylene
cyanol was added at a 1:3 dilution.
All sequencing reaction mixtures were heated to 90°C for 3 min prior to loading onto
the sequencing gel.

The radiolabeled DNA was electrophoresed through an 8%

polyacrylamide/ urea gel (Sambrook, et al., 1989) and the sequence obtained by reading the
X-ray film after autoradiography.
2.7 Reverse transcription-polymerase chain reaction (RT-PCR)
To compare gene sequences among different SHFV isolates, the genomic RNAs of
the prototype (LVR), 1-621, Ph0080 isolates of SHFV, which were passage once in rhesus
monkey macrophages, were purified as described above. The RNA pellets were solubilized
in DEPC-treated water and annealed to 20 pg of an antisense nucleotide primer by heating
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to 90°C for 2 min, 60°C for 2 min, and the solution was then slowly cooled to room
temperature in RT buffer (supplied with reverse transcriptase). The antisense primer was a
synthetic 24-mer, 5 '-TAAAAAGGCTATTACTGCAGGAGC-3', complementary to the 3’
flanking sequence of ORF 7 from the LVR isolate of SHFV. RNasin (40 U), 3 /xg BSA, 10
mM of each of the dNTPs, and 12 U reverse transcriptase (Pharmacia Biotech Inc.) was
added to the annealed mixture and incubated at 42 °C for 1 hr. The resulting specific cDNA
were then made double-stranded and amplified by the polymerase chain reaction (PCR).
Briefly, 4 to 6 fA of the cDNA reaction mixture was added to 20 pg of the antisense primer,
20 pg of the sense primer, 2 mM of each of the four dNTPs, 4 U Taq polymerase (PerkinElmer Corp., Branchburg, NJ) and PCR buffer (supplied with Taq polymerase). The sense
primer, 5'-ATGTACTTATGTTAGGGAGATCG-3, was a synthetic oligomer identical to
the first 23 nt of ORF 7 within the genome of the LVR isolate of SHFV. The ORF 7 gene
was amplified for 30 cycles in a thermocycler (Ericomp, San Diego, CA) in which each cycle
consisted of denaturing the DNA at 94°C for 1 min, annealing the primers to the DNA
template at 56°C for 30 sec, and primer extension at 72°C for 1 min. During the last cycle,
the extension step was prolonged for 7 min.
The resulting amplified SHFV ORF 7 genes were sized on 1% agarose gels, purified
using the Prep-A-Gene DNA Purification System Kit (Bio-Rad Laboratories), and inserted
into the pCR™ 2.1 plasmid vector using the TA cloning kit (Invitrogen Corp., San Diego,
CA). The plasmid DNA was amplified in K coli strain TOP 10F (Invitrogen Corp.) and
screened for inactivation of p-galactosidase gene expression. Minipreps of the plasmid DNA
from selected clones were made using the Quantum Prep Plasmid Miniprep K it The ORF
7 cDNAs made from each of the three SHFV isolates were sequenced as described above.
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For SHFV junction sequence identification, the intracellular viral sgRNA were
isolated as described above. The SHFV sgRNAjunction sequences were reverse transcribed
from the intracellular RNA using cDNA antisense primers complementary to specific SHFV
genomic ORF sequences. These primer sequences are described later in the next Chapter
(Results, Table 3). The resulting SHFV cDNA was amplified in a thermocycler as described
above. The sense primer sequence, 5'-TAGCCCGGATTGGATAAG-3was identical to
nucleotides 60 through 77 of the SHFV 5' leader sequence (Zeng, et al., 1995).
2.8 In vitro expression of the SHFV ORF 7 gene
The ORF 7 cDNA clones were prepared as described above. Clones were linearized
by digestion with the restriction endonuclease Hind ID, extracted with phenohchloroform,
and ethanol precipitated. The cDNA samples were washed in 70% ethanol and resuspended
in water at a concentration of 1 Mg/ Ml- In vitro transcription using the Riboprobe System-T7
was performed as directed by the manufacturer and as described above making both capped
and uncapped mRNA. The capped mRNA was synthesized by addition of 0.5 mM
m7G(5,)ppp(5,)G (Ambion, Inc., Austin, TX) to the transcription mixture. After the DNA
template was digested with RNase-free DNase, the transcripts were extracted with
phenohchloroform and ethanol precipitated. The precipitated RNA was washed with 70%
ethanol, dried, and resuspended in water at a concentration of 1 Mgf Ml- The transcribed RNA
was denatured with 6 M glyoxal (Sigma Chemical Co.) (Sambrook, et al., 1989),
electrophoresed through a 1% agarose gel, and sized by comparing its electrophoretic
mobility with those of RNA standards of specified lengths (Bethesda Research Laboratories
(BRL), Bethesda, MD).
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The transcribed RNA was translated in vitro using the Flexi rabbit reticulocyte lysate
system, the wheat germ extract system, and the rabbit reticulocyte lysate system as described
by the manufacturer (Promega Corp.). The products were analyzed for the amount of [3sS]
cysteine (cpm) incorporated into the protein product by TCA precipitation. Mock reactions
which lacked RNA template was used as control reactions.
Glycosylalion of the ORF 7 product was performed by the addition of 1 y \ of canine
pancreatic microsomal membranes to the translation mixtures as directed by the
manufacturer (Boehringer Mannheim Corp., Indianapolis, IN). The glycosylated ORF 7
translation product was deglycosylated by treatment with 0.2 U of the endoglycosidase Endo
F (Boehringer Mannheim Corp.) at 37°C overnight (Winkler, et al., 1987). An additional
0.1 U of the enzyme was added after 4 hr of incubation in order to obtain complete
deglycosylation o f the glycoprotein. Deglycosylation of SHFV glycoproteins from intact
virion particles were performed using this same method.
2.9 Production of anti-SHFV sera in African green monkeys
SHFV was obtained from infected MA104 cell cultures and the viral protein
concentration was determined by using Micro BCA kit (Pierce, Rockford, IL). Two African
green monkeys were injected intramuscularly (i.m.) with alum-precipitated virus proteins.
The monkeys were boosted at four week intervals and their sera was titered for anti-SHFV
activity by ELISA. Immunization was continued until high anti-SHFV antibody titers were
obtained, after which, blood was collected at six week intervals. Sera was separated from the
blood by centrifuge at 3000 rpm for 15 min. The sera was frozen at -70 °C for further use.
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2.10 Immunoprecipitation
Immimoprecipitation of radiolabeled SHFV proteins from lysates of infected cells or
from the in vitro translation products were preformed using standard methods (Sambrook,
et al., 1989). African green monkey anti-SHFV sera was diluted ten-fold in lysis buffer
containing the protein sample to be immunoprecipitated and incubated for 4 hr. Meanwhile,
rabbit anti-monkey IgG (Jackson ImmunoResearch Laboratories, Inc, West Grove, PA) was
bound to protein A sepharose (Sigma Chemical Co.) for 4 hr in lysis buffer containing 1%
BSA. The rabbit anti-monkey IgG-sepharose was added to the anti-SHFV-protein mixture
and incubated for an addition 4 hr. The mixture was then centrifuged at 3000 rpm for I min.
The pellets were washed five times with lysis buffer and analyzed by SDS-PAGE. All of the
incubation steps in this procedure were carried out at 4°C.
2.11 Genetic immunizations
The cloned ORF 7 gene of SHFV was excised from the pCR™ 2.1 plasmid vector
using the restriction enzymes Hind III and Xho I and inserted into the pcDNA3.1/Zeo(-)
vector (Invitrogen Corp.) using these restriction sites. After amplification in E. coli., the
plasmid was purified by equilibrium centrifugation in CsCl-ethidium bromide gradients
(Sambrook, et al., 1989) and sequenced to substantiate the correct orientation and sequence.
The concentration of the plasmid DNA was determined by absorbency using a
spectrophotometer at a wavelength of260 nm. DNA (50 jig) was injected iun. into BALB/c
mice on weeks 0,2 ,4 , and 10. Blood was obtained from these mice through the retro-orbital
sinus at week 11. Sera was separated from the blood by centrifugation and assayed by
ELISA for the presence of anti-ORF 7 antibodies.
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2.12 Monoclonal antibody (mAb) production
In the beginning of this project, mice were immunized to SHFV proteins by Dr. M.
Philpott (School of Veterinary Medicine, Louisiana State University). Briefly, BALB/c mice
were injected with 100 ng of MA104 cell lysate by the intraperitoneal (i.p.) route. The mice
were injected with cyclophosphosphamide seven days later at a dose of 40 mg/kg body
weight to eliminate activated B-cells to the MAI04 cell antigens. One week later, 100 /zg
of purified SHFV was injected i.p. into the mice, followed by an additional three booster
immunizations at two week intervals. Prior to boosting, sera was collected from the mice
and assayed for anti-SHFV activity by ELISA. Alternatively, mice were genetically
imm unized with the SHFV ORF 7 gene as described above.

Hybridoma cells were made from the splenic lymphocytes from the immunized
BALB/c mice. Three days after the final booster immunization, the mice were euthanized
and their spleens were removed.

Splenic lymphocytes were released, washed, and

resuspended in RPMI 1640. Red blood cells were removed by treatment with 0.83% NH4C1
for 2 min. After which, the cell suspension was centrifuged at 300 X G for 10 min at room
temperature. Meanwhile, myeloma cells (X 63) were harvested and treated with NH4CI
similarly. The splenic and myeloma cells were counted, mixed at a ratio of 4:1, and
centrifuged at 300 X G for 5 min. The cell pellets were then treated with 50% PEG and, after
1 min, RPMI 1640 was added to the cell mixture and the cells were pelleted. The cell pellets

were resuspended in RPMI 1640 containing 20% FCS and distributed into 96 well plates
(Costar Corp.). After a 24 hr incubation, RPMI 1640 medium containing hypoxanthineaminopterin-thymidine (HAT; Sigma Chemical Co.) and 20% FCS was added to each well.
Half of the supernatant was removed from each well and replaced with the fresh HAT
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medium daily for three days, after which, the medium was replaced every 3 to 5 days. The
hybridoma cells were maintained in HAT medium for a m inim um of 3-4 weeks.
Supernatant fluid from each well positive for growth was screened for anti-SHFV
activity by ELISA after 14 days. All wells which exhibited anti-SHFV activity were
transferred to 24 well plates (Costar Corp.). Upon confluency, supernatant fluids from the
cell cultures were retested by ELISA. Cells which remained positive for anti-SHFV activity
were split and stored in liquid N2 (-196°C) until needed.
Hybridoma cells were cloned by the limiting dilution method. Briefly, hybridomas
were plated into 96 well plates at 10, 1, and 0.1 cells/well in the presence of peritoneal
exudate cells removed from normal, healthy, adult BALB/c mice. These cells were used at
a concentration o f200 cells/ well.
After seven days at 37°C in a 5% C02, humidified environment, all wells were
examined by light microscopy. Wells which contained single, actively growing cell clones
were marked and fed with fresh complete RPMI-1640 medium containing 20% FCS. At 14
days, the clones were tested by ELISA and positive clones were transferred into 24 well
plates. The supernatant from the 24 wells plates were further tested for anti-SHFV antibodies
by ELISA. Positive clones were frozen as soon as possible.
Ascites fluids from mice were used to produce the mAbs as follows. Six to ten week
old BALB/c mice were injected with 0.5 ml incomplete Freund’s adjuvant i.p. (Sigma
Chemical Co.). Seven to ten days later, 106hybridoma cells were injected into these mice i.p.
Ascitic fluid was harvested within two weeks and mice were “tapped” every other day
thereafter until abdominal tumors necessitated their euthanasia. Ascites fluids were
centrifuged to remove cells and were tested for anti-SHFV antibodies by ELISA. Ascites
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fluids co ntaining the antibodies from the same hybridoma were pooled, divided into aliquots,
and stored frozen at -70 °C
mAb isotypes were determined by the ImmunoPureR Monoclonal Antibody Isotyping
Kit II using the antigen-independent technique according to the manufacturers instructions
(Pierce Chemical Co.).
2.13 Enzyme-linked immunosorbant assay (ELISA)
Microtiter plates (Costar Corp.) were coated with 0.2- 0.4 ug/ well of SHF viral
antigens in a carbonate buffer (0.1 mM N a^O j and NaHCOj, pH 9.6) for 4 hr at room
temperature. Then, nonspecific binding sites were blocked with 3% fish gelatin (Sigma
Chemical Co.) in carbonate buffer. The antigen-coated wells were incubated with dilutions
of various samples to be tested for 30 min at room temperature. After washing 5 times with
washing buffer (NET; 0.15 M NaCI, 1 mM EDTA, 0.05 M Tris (pH 7.4), and 0.05% Tween
20), the antigen-antibody complex was then incubated with horseradish peroxidase-labeled,
species-specific anti-IgG antibodies (Jackson ImmunResearch Laboratories, Inc.) for 30 min
at room temperature. The wells were washed an additional 5 times and then incubated with
substrate, 3,3',5,5 '-tetramethy1benzidine dichloride as directed by the manufacturer (TMB,
Kirkegaard & Perry Laboratories, Inc., Gaithersburg, MD) for 15 min. After the color
change was observed, the reaction was stopped with 0.1 M H2S04 and the results were read
on an ELISA reader (Dynatech Lab., Chantilly, VA) at 450 nm.
2.14 Western blot analysis
SHFV proteins were separated by SDS-PAGE (Laemmli, 1970) and
electrophoretically transferred to polyvinylidine difluoride (PVDF) membranes (Bio-Rad
Laboratories, Inc.). The nonspecific binding sites on the membrane were blocked with
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blocking buffer (NET containing 10% nonfat dry milk) overnight at room temperature. The
blots were then washed five time with washing buffer (NET containing 0.05% Tween 20)
for 5 min each at room temperature, after which, the membranes were incubated with the
primary antibodies (supernatant fluid from hybridoma cells or diluted anti-SHFV polyclonal
serum) for 1 hr at room temperature. The membranes were rewashed and horseradish
peroxidase-conjugated, species-specific, anti- IgG antibodies added to the blots for 1 hr.
After additional washing with wash buffer, the blots were incubated in the horseradish
peroxidase substrate, TMB plus enhancer (Kirkegaard & Perry Laboratories, Inc.) for 10 to
20 min as directed by the manufacturer. The membranes were rinsed in water to stop the
reaction and then the blots were analyzed visually.
2.15 Competitive binding assays
Direct biotin-labeling of the mAbs was performed using sulfosuccinimidobiotin
(Immunopure® Sulfo-NHS-Biotin; Pierce) as directed by the manufacturer. After the
incubation step, all unreacted biotin was removed from the mixture using a
microconcentrator (cut size 30, 000; Amicon Inc., Beverly, MA) and the biotinylated mAbs
were stored at 4°C.
Competitive binding assays were performed using a modified ELISA. Briefly, 0.05
pg of SHFV proteins in carbonate buffer were bound to microtiter plates for 8 hr at room
temperature. The nonspecific sites were blocked by adding 3% bovine albumin (Sigma
Chemical Co.) in NET containing 0.05% Tween 20 overnight at room temperature.
Unlabeled mAbs (Abl) were concentrated from supernatant fluid approximately 2-3 folds
using a microconcentrator and 100 (A of concentrated Abs were added to the SHFV-coated
wells and incubated for 1 hr at 37°C. The plates were washed twice with wash buffer and
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the above procedure was repeated for an additional three times in order to block all of the
specific viral epitopes. Next, the biotinylated mAbs (Ab2) in dilution buffer (NET
containing 0.5% BSA) were added to the wells and incubated for 1 hr at 37°C. The plates
were washed 5 times with wash buffer and incubated with horseradish peroxidase-conjugated
streptavidin (Pierce) in dilution buffer for an additional hour at 37°C. After washing, the
TMB substrate was added to each well for 15 min. The reaction was stopped by the addition
of 0.1 M H2S04and the optical density of each well was determined on the ELISA reader at
450 nm. The degree to which Abl hindered or blocked the binding of the second antibody,
Ab2, was determined by the following equation:

% Blocking Ability =

1 -

OP Blocked
OD Unblocked

X 100%

The ability of each mAb to block its own binding i.e., Abl =Ab2, in this type of assay was
also measured.
2.16 Animals
All animals used in this study were housed in the vivarium located in the LSU,
School of Veterinary Medicine. The animals were handled and cared for according to
methods approved by the LSU Institutional Animal Care and Use Committee.
2.17 Computer analysis
The translation of the SHFV ORFs, the characteristics of the deduced peptides, and
the hydrophobic pattern according to the method o f Kyte and Doolittle (1982) of specific
ORFs were determined by the Translation and Protein Analysis programs, respectively,

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

37

supplied in the University ofWisconsin Genetics Computer Group (GCG) software (Program
Manual for the Wisconsin Package, Version 8).
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3.

RESULTS

3.1 Sequence of the 3' end of SHFV RNA genome.
In order to identify the SHFV large envelope glycoprotein gene it was first necessary
to clone and sequence the entire 3' end of the viral genome which presumably contains the
ORFs encoding the viral structural protein genes. The first 806 nucleotides from the poly(A)
tract at the 3' end of the SHFV genome were previously reported (Godeny, et al., 1995).
Beginning with the published sequence, primers were synthesized (Table 1) and the 3' end
of the SHFV genome was cloned and sequenced using a “walk along” method as described
in Materials and Methods. Because there is no proofreading mechanism during RNA
transcription, at least three clones were sequenced for each nucleotide in order to obtain the
majority SHFV genome sequence.
After cloning and sequencing over 40,000 nucleotides, a 6,314 nucleotide sequence
was obtained representing the entire 3' end of the SHFV genome (Fig. 2). This sequence has
been deposited with and can be accessed from GenBank using the accession number U63121.
At the 3’ terminus of this sequence is an 11 nucleotide poly(A) tract followed by the 76
nucleotide noncoding region, as previously described (Godeny, et al., 1995). The ORF lb
genes of the arteriviruses contain four conserved domains. The helicase (domain 3) and the
carboxy-terminal (domain 4) domains are found within the partial ORF at the 5’ end of the
sequence, suggesting that the first 1,590 nucleotides of this SHFV sequence represents the
3’ end of the ORF lb gene.
Between the SHFV ORF lb gene and the 3’ noncoding region, there are nine SHFV
ORFs which includes three additional ORFs as compared to the other arteriviruses (Fig.3).
38
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Table 1. Primers used for cloning and sequencing the SHFV RNA genome
Primer
SHF465
SHF749
SHF868
SHF995
SHF1I36
SHF 1293
E25-R623
SHF 1608
E25-R333
SHF1971
E25-R138
SHF2087
SHF2241
SHF2372
SHF2586
SHF2718
G1A
GIR
G2
SHF3094
G3
G4
G5
G6
G7
G8
G9
G10
G il
G12
G13
SHF5060
SHF5170
SHF5397
SHF5578
SHF5607
SHF5742
SHF5835
SHF5955
SHF6055
SHF6221
SHF6248
SHF6301

Primer Sequence(5'—K3')
CCCTTCCATTGAGTATG
GCATAAGCAAGTGTAGC
GGGTCACTGCAAAGGGATAC
GGGTCGGAAATCAGCACG
GTAATAGTTTGTCCTGC
AAGAACTAAGGTGTGTG
TTCCGTCATTGCTGCTGAG
GATGTAGATGAGGTGCGG
TTGTTATCATGACTCAGG
GACCATAGTCTCGTGTTCG
TCGAACACGAGACTATGG
TTGCTGGTAGTAGTAGGC
GGAGGAGTAAGTAAGG
GCTGTTGGTAGCACTGTGTC
AGCAGAAGACGACCGCAG
CCAACGCTCGATTCTTCG
CTGGTCTTCTGCCTTCTG
GGTGAATGCACTGGCGG
TGTAAGCGCCTCGGGACG
GGTCAAAGAACGAGACGAGG
GGCTGTAGTGATGTGGGTG
AGCAGAGGACGATATGG
ATTGTCTCATAGGTCTC
GGTAATGTTGGTATGATG
GGATGTAGTA
GTGTAGTTGCGGCTG
GGCATAGACGTGCTGATGAG
CTAGGGGTACATACAACGG
CGAACGCACAAGGAG
AGTAAACGCGCCGAACCC
ACTCATCAGAGGAGAGGG
CTTATAGAAATACACAGG
ATGGGCGTCACGTCAGGG
CAGAGTGCTTTGTGAGCG
AAATAATCCCTGATATCC
GCCAGTGGAGTAAACAG
GATAGAGGTGACAGCCG
TCAGATGGAATGGGGAG
CTCTTCCAAAATCCGAC
ACTCGCGCCTTGCCATC
GGTAGGCAGGTACAGAGTG
GTCGACCCTTGAGAG
GATATGGGGTAGTAG
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Distance to
3' end (nts)
465
749
868
995
1136
1293
1541
1608
1830
1971
2024
2087
2241
2372
2586
2718
2852
2882
2975
3094
3139
3299
3435
3568
3714
3812
3874
4063
4348
4533
4768
5060
5170
5397
5578
5607
5742
5835
5955
6055
6221
6248
6301
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Figure 2: The nucleotide sequence of the 3' end of the SHFV genome and its deduced
amino acid sequence. Position 1 is the 5' end of the nucleotide sequence and position
6314 is the 3' terminus. The nucleotides encoding the arterivirus conserved ORF lb
putative helicase (domain 3) and carboxy- terminal (domain 4) domains are underlined
and double underlined, respectively. sgRNA junction sequences are in bold type and
double underlined. The ORFs are numbered and the potential N-Iinked glycosylation
sites are underlined. Termination codons are indicated by an asterisk (*). The location
of each of the ORFs, the deduced ammo acid sequence, and the potential N-linked
glycosylation sites were determined from the SHFV genome sequence using the GCG
Translation program.
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•

•

•

•

•

•

AGTACTACCCCATATCACAGGGACAGAGTTGGTGCAGCGGTCACAATTGACTCCTCTCAA
S T T P
Y H R D R V G A A V T
I Q S 3 Q__
•

•

•

•

•

•

GGGTCGACCTACGACGTGGTCACTCTGTACCTGCCTACCAAAGGCAGTCTGACACTGGCT
G S T Y
D V V T L
X L
P T B £ __ 3
L I
L— ft .
•

•

•

•

60

•

120

•

CGTGGTTTAGTAGGAATCACTAGAGCCCGAGAGAGGTTGTATGTTTATGACCCGCATCAT
R G T .
V G I T R A R E R
L Y V Y D P H H

180

CAGCTCGCAAAGTACTTTAATCTTCAGCCGTCCAGCACCACAATTCGGCCTCATGCTGTA
Q L A K Y F N L Q P S S T T
I
R P H A V

240

GTCATCGATGGCAAGGCGCGAGTCATGCTGTCTGACAAGTGCTACGCTGCCCCAGAGGAC
V I
D G K A R V M L S D K C Y A A P E D

300

TTCCCGGGCATGCTCTGCACTGCGAGGAACGCTACCGCGGCTGACAGGAAGATTTTGGAA
F P G M L C T A R N A T A A D R K I L E

360

GAGACTTGCCTCAAATTAGATTTTCTTGAATCTGGCTCACTGTCCCCTCTTCCCCGTGTG
E T C L K L D F L E S G S L S P L P R V

420

TGCTATAATCTAGGGTTCTATTACTCACCAGACATTACCAAATTGCTCCCCATTCCATCT
C Y N L G F Y Y S P D I T K L L P I P S

480

GAATTGGCAAAACACTGGCCCGTCGCGACTAACCGGAATAATCCAGAGTGGCCCAATCGT
E L A K H W P V A T N R N N P E W P N R

540

CTAGTGGTTTCAGCCACCCGGCTGTCACCTCTATCACATCCGGCCGTGTGCGCAGGTTAC
L V V S A T R L S
P L S H P A V C A G Y

600

TACGTGGGGGACTCACTCTTTGTTGGTACTCCAAACGTGACCTCGTACTGGTTGACGAAG
Y V G D S L F V G T P N V T S Y W L T K

660

TTTCTAGATGGTCGGGCTGTTCCTATGGAAGATTCTGTTTACTCCACTGGCCGGTTTGAA
F L D G R A V P M E D S V Y
S T G R F E

720

ATGGATATCAGGGATTATTTGGATTCAGCTGAAAGGGATTTCGCTGCTAAGCACCCACAT
M D I R D Y L D S A E R D F A A K H P
H

780

GCTTTCATCGGCGATACGAAGGGCACGACTGTTGGTGGTTGCCATCATATCACCTCACAG
A F I G D T K G T T V G G C H H I T S O

840

•

•

•

•

•

•

TACTTGCCCCATGTGCTACCTGCCGACAGTGTTGTCAAGGTTGGTGTCAGCAAGCCTGGG
Y L P H V L P A D S V V K V G V S K P G

900

GTCGCTCACAAAGCACTCTGTACGGTAACTGATATCTACCTCCCGATGCTGGGCTCGTAC
V A H K A L C T V T D I Y L P M L G S Y

960

ACATCACCTCCCACTCAGTCTAAAGTCTACAAAGTAAATGTTGACCACAAGGCGTGCAAA 1 0 2 0
T S
P
P
T O S K V Y
K V N V D H K A C K
CTCATGGTCTGGCGTGACCAGACAATGTACTTCCAAGAGGGTTTTGATTATCACACGCTC 1 0 8 0
L M V W R D O T M Y F O
E G F D Y H T L

(Figure 2, cont’d)
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•

•

•

•

•

•

GTGGATGCACTCCGGTTCGTCCGCTTGAGCAGTGATGGGGTCTATCGCGTCGCCCCTGAC 1 1 4 0
V D A L R F V R L S S D G V Y R V A P D
GTGACGCCCATGATTGGCAATAGGAGGTTGGACCTGGGCGCTAAACCTCTGAGACCCGTT 1 2 0 0
V T P M I G N R R L D L G A K P L R P V
GATTTGGCTATCACCCCTTGGGATGACCCCAAATGTGAGTTTCTGGTGACACACGCCTCC 1 2 6 0
D L A I T P W D D P K C E F L V T H A S
CCATTTGACATGTCTGATGAGTTTCTTCTAGTCAATGCTTTTGATTTCATCAAGGAGGAT 1 3 2 0
P F D M S D E F L L V N A F D F I K E D
CTGCTAGGCAAATCTGTCACACCTGTGTATTTCTATAAGAGGCTTTCTGAACCCTTGCAT 1 3 8 0
L L G K S V T P V Y F Y K R L S E P L H
TTTGACCAAAATCTGCCGCCTCATGTTGGAGCTATCCTGTCCAAAGCACCCCGCTTTATA 1 4 4 0
F D Q N L P P H V G A I L S K A P R F I
TCTCTAGCCAAGGTCTTTAACTTCTGTTTCACACCTACAGCCTGTCACTGTAAGGTGTCA 1 5 0 0
S L A K V F N F C F T P T A C H C K V S
GTTAAGACCGCCACAGGTGACCACATGTGTAAATGCTCCCTCTCCTCTGATGAGTTTCTG 1 5 6 0
V K T A T G D H M C K C S
L S S
D E F L
O RF2a
M S F C
4
•

•

•

•

•

•

TCCAGGTTTAATCCTACTGTTGGTACTCCTTAAACCAGTCGACTCTTTTGATTTCTTTCA 1 6 2 0
S R F N P T V G T P *
P G L I L L L V L L K P V D S F D F F H
24
CTTCTCCTCCTCCTTCAAGTACTATGATCACACCCACATTCATACTGTTTTCAGAGATCT 1 6 8 0
F S
S S F K Y Y D H T H I
H T V F R D L
44
TATTTCCCATTGCGAAACAAAAATTGCGCCGTGGGCTAAACATCCTCTTGGAATCATTGG 1 7 4 0
I S H C E T K I A P W A K H P L G I I G
64
GCACAATCAATTTGTATCTGCCTACAACAATTGGGTTCGGCGCGTTTACTCCGTCAACCC 1 8 0 0
H N Q F V S A Y N N W V R R V Y S V N P
84
•
•
•
•
•
CATTTATATTGAGGCAGAGAAGGGTTTCAAACATTACTACAGTTACAAGCCCGAGTGCAG 1 8 6 0
I Y
I E A E K G F K H Y Y
S Y K P E C R
104
•

AAGTCAAATTGGCTATCCCGCCACAGTACACGCAGGTACTCGAGAAATCGACTTGCCTAG 1 9 2 0
S Q
I G Y P A T V H A G T R E I
D L P R
124
ACTGCTGACTGCACTTAAAACCTATTCAGTGAAGGAACACTCCTTGTGCGTTCGGGCTGC 1 9 8 0
L L T A L K T Y S V K E H S L C V R A A
144
•
•
•
»
•
•
CGGATTGCTCGCCCGTCTGCATGAGTTGAGGAAACAAGAGGATTTCAACATCACTGATGA 2 0 4 0
G L L A R L H E L R K Q E D F
N I T
D D
164
•

•

•

•

«

•

TACCTTCACCATCAATTATCACTTGAAGGAGAGTTCTGTACCATGGTTTCAATCTGGTTT 2 1 0 0
ORF2b
M V S I
W F
6
T F T I N Y H L K E S S V P W F Q S G F
184

(Figure 2, cont’d)
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»

•

•

•

•

•

CTACTTGCAGGTCTATCATGCTTCCAGTTTTGCCACGTTTATTGCACCCTTAACTTTACT 2 1 6 0
L L A G L S C F Q F C H V Y C T L
N F T
26
Y L Q V Y H A S S F A T
F I A P L T L L
204
•
•
•
•
•
AATAGTTCTTCTGATTCGCAAACCCCGGTTGCTTGCTTTCATCTGCCCAGCGGTAACGTG 2 2 2 0
N S S S D S Q T P V A C F H L P S G
M
46
I V L L I R K P R L L A F I C P A V T C
224
•

TCGTTTTCAATCAACCTCACAGCCGTTGTATGTACCCCTAGTTGGAATAAGACCGGGCCC 2 2 8 0
S. F S
I
N L T A V V C T
P S W
N K T G P
66
R F Q S T S Q P L Y V P L V G I R P G P
244
TTCATTCTCACCTACGGGCGTCTCAGCGCCTCAACGCATGAGTGCACCTCGATTCGTGCG 2 3 4 0
I
I L T Y G R L S A S T H E C T S I R A
86
S F S P T G V S A P Q R M S A P R F V R
264
TCTTCCGGTGGGCTCTGGGCAGATCTTAGCATCTGGGAAAGGCCAAGGTCTGTAACTGGC 2 4 0 0
S S G G L W A D L S I W E R P R S V T G
106
L P V G S G Q I L A S G K G Q G L *
281
ATCTTTAATTTCACTGATCAGCTCGCTGAATCTCATCAGCACGTCTATGCCCTCTTCATA 2 4 6 0
I
F N F T
D Q L A E S H Q H V Y A L F I
126
GCTGCCTTAACCTTTCACCCTGAACTCTTTGGTCTCAGCCGCAACTACACTCGTTCCCTA 2 5 2 0
A A L T F H P E L F G L S R
N Y T R S
L
146
ACAATCAAGCAATCATGGAACGAGACAATGATGTGTGTAAACGGCACTGTAGTGTTGACA 2 5 8 0
T
I
K Q S W N E T
M M C V N G T V V L T
166
ORF 3
M E R D N D V C K R H C S V D K
16
•
•
•
•
•
•
AACGCTACTGCGGCCGAGTACTACATCCGCACGGGGGTAGATTCGCCTATGTACTTTGTG 2 6 4 0
N A T
A A E Y Y I R T G V D S P M Y F V
186
R Y C G R V L H P H G G R F A Y V L C G
36
•
•
•
•
»
•
GAATTGTTGCGGCCCTTTCTTCTGTGCCTGCTAATTCTAATGCTGAGCGATGTATGATTT 2 7 0 0
E L L R P F L L C L L I
L M L S D V *
204
I V A A L S S V P A N S N A E R C M I C
56
GCACCACAAACAACTTCTCTACATTGTTCACTGAATCATCATACCAACATTACCCCCGCT 2 7 6 0
T T N N F S
T L F T E S S Y Q H Y P R W
76
GGCCTGTCTTTCAAGACGGACTCGACTATGTCTATCGTCCACCACTTGTCGCCCAAGTTC 2 8 2 0
P V F Q D G L D Y V Y R P P L V A Q V L
96
TGGGTTATGGCGAAACGTGTGATGATACACAAATCATTGGCACCATAATTGAGACCTATG 2 8 8 0
G Y G E T C D D T Q I
I G T I I E T Y E
116
AGACAATTACAGGCAACATGACTGGTATCAAAGAAGCTTTCATTGCTCTTGACTTTGCTG 2 9 4 0
T
I
T G N M T G I K E A F I A L D F A D
136
ACTGTTTACTCACTGGCATTCTTTACCGGGAACACAACGTGACAGCAGTTTTCCAGCAAC 3 0 0 0
C L L T G I L Y R E H
N V T A V F Q Q Q
156

(Figure 2, cont’d)
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AGGATGGCCATATCGTCCTCTGCTGGAACGGGACTGATCCTAGGATTTCTATTAACCAAA 3 0 6 0
D G H I V L C W
N G T
D P R I S I N Q I
176
•

•

•

•

•

*

TACCTACTCCTTGGTTCATCTCGCCAGGAGCGCTCAGGTGGGCAACCATCATTTGCGCAT 3 1 2 0
P T P W F
I
S P G A L R W A T I
I C A C
196
•

»

•

•

•

•

GCTTGGCGATCTTTAGAGCATTCTATTCTTAATGGGTTCTATACTCACCCACATCACTAC 3 1 8 0
L A I F R A F Y S *
205
AGCCTTCCACCATGCTGTCCACGAGCTCCTCGTCTCGTTCTTTGACCTGCTCATCTATAT 3 2 4 0
ORF 4 M L S T S S S S R S L T C S 5 I W
17
•

•

•

•

•

•

GGCTGTTATCATTCTTGCTCTGCTGGTTGGTAAAATGCTCTCACTCACAATTAAATCTAT 3 3 0 0
L L S F L L C W L V K C S H S Q L N L F
37
•
•
•
TTTCCGCTGTGCCTCAACAGTTGCGCCTACGTCCCGAGGCGCTTACAAAAATGCTTTTGC 3 3 6 0
S A V P Q Q L R L R P E A L T K M L L R
57
•

•

•

GCCGGTGTCATCAAAGTATCATACCTTACCCTAACCATCCTCTGGGTATCACCACGCATG 3 4 2 0
R C H Q S
I
I P Y P N H P L G I T T H A
77
•
•
•
•
•
•
CGATGGTGAATGCACTGGCGGCCTTTAGTCTTCAGAAGGCAGAAGACCAGGCCCATGCCA 3 4 8 0
M V N A L A A F S L Q K A E D Q A H A T
97
CCCTTCATGTCAAAGGCATCACTTCAGCTGAGTACACCTACAACGTTTCGTGCGAACCCA 3 5 4 0
L H V K G I T S A E Y T Y
N V S C E P S
117
GTTCTTTCACCCTCGACGTGACTGGACTTTCTAAATACCTCACCTCGAAGAATCGAGCGT 3 6 0 0
S F T L D V T G L S K Y L T S K N R A L
137
•

■

•

•

•

•

TGGAGAGACTTCGCCACTGCGAAGACATCGCACCAATTGTGGGTTACTTGCTCTCAAACA 3 6 6 0
E R L R H C E D I A P I V G Y L L S
M £
157
•

•

•

•

•

•

GGACGCACAGTTATCTCACTAACCCATGGATGTCCGTGGTCCTCAAGTCACACAGGCCTG 3 7 2 0
ORF 5
M D V R G P Q V T Q A C
12
X H S Y L T N P W M S V V L K S H R P A
177
CGGTCGTCTTCTGCTACTATGTTTGCTGTTTCTTACTTGTTCTGCAAATCAAACACATAT 3 7 8 0
G R L L L L C L L F L T C S A
N O T
H I
32
V V F C Y Y V C C F L L V L Q I K H I
F
197
•

•

•

•

•

•

TTGCTTTCGTAACATACAAACTCAGGTCAAGTTGCACTTCAACACCTCAGTCCTAGCTTG 3 8 4 0
C F R N
I Q T Q V K L H F
N T S
V L A
C
52
A F V T Y K L R S S C T S T P Q S *
214
•

•

•

•

•

•

CCTGTACCGTGGCAACGTTGTCATTGACCAAAACATAGAACCGGCCTGCTCAGGCCCCAC 3 9 0 0
L Y R G N V V I D Q N I E P A C S G P T
72
•
•
GGGTATCCAAACCCGTCAATCTGACAGCGAGGACACAGTGCTACCAACAGCAATTGATTT 3 9 6 0
G I Q T R Q S D S E D T V L P T A I D L
92
»

•

•

•

•

•

«

•

•

*

GGATTTCCTGGCTCTTCTTCTGCACTCACTGAAGTACTTCCCAGTTCTTTTCAACGCCAC 4 0 2 0
D F L A L L L H S L K
Y F P V L F
N A T
112

(Figure 2, cont*d)
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TTCTGTCCAGTTTGATAACGAGACATTATGCTACATTGCAAACCTTACTTACTCCTCCAA 4 0 8 0
ORF 6
M L H C K P Y L L L Q
11
S V Q F
D N E T
L C Y I
A N L T
Y S
S ££
132
CTCTACATCGTTGCTTGGCACTACTGTGGCTTACTGGGAGACACAGCCGCTGCCAGTTCT 4 1 4 0
L Y I V A W H Y C G L L G D T A A A S S
31
S
1
S L L G T T V A Y W E T Q P L
P V L
152
ACTCCTCATACTGTGTCTTCAAATTTGCCTACTACTACCAGCAATCCCCCCCGTGCCGAA 4 2 0 0
T P H T V S S N L P T T T S N P P R A E
51
L L I L C L Q I C L L L P A I P P V P K
172
GAATTCGGGGATCAAACTTGCTTGATTTGCCTTCCCCATCCAAATCGCACTTCTTTGACT 4 2 6 0
E F G D Q T C L I C L P H P
N R T
S
L T
71
N S G I K L A *
179
TTTGACCTTGCGGAACAAAGTTCGAACACGAGACTATGGTCATCGGGTTGCCTCACAAAT 4 3 2 0
F D L A E Q S S N T R L W S S G C L T N
91
CTCAAAGGCGGCGTGACAACAACCAGCATCAACGTCACAGTTTCTTCACCTGTCGACCAC 4 3 8 0
L K G G V T T T S I
N V T V S S
P V
D H
111
GTCCTAGCATTGGGACATTGCCTAGCTTTGGCAATCCGATTAGCCGCCCATAACCATAGT 4 4 4 0
V L A L G H C L A L A I R L A A H N H S
131
GTGTTCTTCGCCAATCACAGTGATAATCTGTATCTTTGTTATCATGACTCAGGTATATTT 4 5 0 0
V F
F A N H S
D N L Y L C Y H D S G I F
151
•
CAGCCTATCACCGCGATCCATCCAGGTGCGTTGCGGTGGGCTTCCATCATAACCTTGTTC 4 5 6 0
Q P I T A I H P G A L R W A S I
I T L F
171
•

•

•

•

*

ATTGTGATTGCGCGACTCCGCTCCTTAACTACCTAATTATGTACTTATGTTTAGGGAGAT 4 6 2 0
I V I A R L R S L T T *
182
ORF 7
M Y L C L G R S
8
CGGAGACTCCGTTGATAGGTTTGTTCCGCACCTCATCTACATCTATCTCATGGTTCTATG 4 6 8 0
E T P L I G L F R T S S T S I S W F Y V
28
»
•
•
•
•
•
TGCTTTTCTTTGTCTCTATTACATTCAGCAGCACCGGCgCATCCGAGAACAACACCGGTA 4 7 4 0
L F F V S
I T F S S T G A S E
N N T
G T
48
•

•

•

•

•

•

CGACCTGGATCAGCATATCAAAGTTTCCGTCATTGCTGCTGAGTCAGATCATAAGCCCTA 4 8 0 0
T W I S I S K F P S L L L S Q I I S P S
68
•

•

•

•

•

•

GTTACATTGTAAATATCTCTGTCTGTGGTGCATTTGACATTCAAAATAACACTCACTGGT 4 8 6 0
Y
I
V N T S
V C G A F D I Q
N N T
H W F
88
•

•

•

»

•

»

TCACTCCTTGTAATTTGTCTGTCTTGAATCACTCTGACTGTCACACGTGTAAGTCAGAGC 4 9 2 0
T
P C N L S
V L N H S
D C H T C K S E Q
108
AGTCAAACCAATCTTTATTATCAAATTGTTCAACGTGTTTCACACACCTTAGTTCTTGTT 4 9 8 0
S
N O S
L L
S
N C S T C F T H L S S C F
128
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•

.

•

•

•

TTCTTCACACTTACACTGGACACCACATCAATAACACTAGGCTTCTTTTAGAGACATATT 5 0 4 0
L H T Y T G H H I
N N T R L L L E T Y L
148
•

•

•

•

•

•

TAGCAGTCCCCTTACTAACCCATTTATTGAGTTATAAGTTTGCTACAACTGCCTCCTTTC 5 1 0 0
A V P L L T H L L S Y K F A T T A S F L
168
•
TTGACTTTGCCTTTTTTGCAGGACTTTCTATTACGGCCTATCGCTATGTTTCACCGGCGA 5 1 6 0
D F A F F A G L S I T A Y R Y V S
P A I
188
•

•

•

•

•

•

•

•

•

•

*

TATTATTCTTCTTGCCACTCGCTCTCATCTTCTCGGCTATCTTCATCAAGAAGTTAGTGG 5 2 2 0
L F F L P L A L I
F S A I F I K K L V V
208
•

•

•

•

•

*

TAAATTGTATGGCCCTCCGCTTCGCGTGGACTAGGCACACCAATTTCATCATTGACGACC 5 2 8 0
N C M A L R F A W T R H T N F I
I
D D R
228
»

•

•

•

*

*

GAGGTAGATTATTTGTCAACCACGACGACGTGCTGATTTCCGACCCACAGGGACTGCGGG 5 3 4 0
G R L F V N H D D V L I S D P Q G L R V
248
•

•

•

•

•

•

TTGGACCTCATAAGGTCAGAGCCGCTAAGGTAATACTTGGTGGACGGGAGGCAAATTTAC 5 4 0 0
G P H K V R A A K V I L G G R E A N L L
268
TCAGACAAGCACACGTCGAAGAGTGGTCATGGTAGTATCCCTTTGCAGTGACCCGGGGTA 5 4 6 0
ORF 8 M V V S L C S D P G Y
11
R Q A H V E E W S W *
278
.

.

•

•

•

•

CACTACCTTGGCTTTTACTATTGCTCCTGCATTAATAGCCTTTTTAAGATATTTCCGCCC 5 5 2 0
T T L A F T I A P A L I A F L R Y F R P
31
«

•

»

•

•

•

ATCCGTGCGCGGTTTCATATGCTTGGTATGCATTGCTACACTTGCTTATGCTGCAACTGC 5 5 8 0
S V R G F I C L V C I A T L A Y A A T A
51
•
•
•
•
•
•
TTTCAATGAACATTCCCTTGCAACATTACTAACAATTGGGTTCAGTCTGGTATACTTGAC 5 6 4 0
F N E H S L A T L L T I G F S L V Y L T
71
CTATAAATTCATCACGTGGACCATTCTACGTGTGCGGATGTGTTGGCTCGGCCGGCAATA 5 7 0 0
Y K F I T W T I L R V R M C W L G R Q Y
91
»

•

•

•

»

•

CATAACCGCCCCTTCCAGTATGGTTGAGTCATCCCTTGGCCGTTTAGCGATTAACGCGAC 5 7 6 0
I T A P S S M V E S S L G R L A I
N A T
111
TGGTTCTACCGCAGTCGTAACTCGCCGATCTGGCATGACAGCAGTCAATGGTAGTCTCAT 5 8 2 0
G S T A V V T R R S G M T A V
N G S
L M
131
•

•

•

•

•

*

GCCGGATGTGAAAAGGATCATACTCAATGGAAGGGTTGCCGCCAAAAGGGGTCTTGTTAA 5 8 8 0
P D V K R I
I L N G R V A A K R G L V N
151
•

•

•

•

•

*

CCTGAGGAAGTATGGCTGGCAAACCAAAAACAAATAACAAGGGAAAATCCCAGTCCAGAG 5 9 4 0
L R K Y G W Q T K N K *
162
ORF 9 M A G K P K T N N K G K S Q S R G
17
•
•
GAGGGAATAGGCTTCCCCAACGACCTCGCCGCAGCACTCAACAACGTAGAGCTGCTCCTG 6 0 0 0
G N R L P Q R P R R S T Q Q R R A A P V
37
•

•

•

*
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•

•

•

•

•

•

TCCACAAGCCTCTAAATGAGACACATTATGTTTTCGCCGAACCCGGCGACCTCCGAGTTG 6 0 6 0
H K P L M K T
H Y V F A E P G D L R V V
57
TTCTACCTGGTCCCACCTCAGCACACATCAAACAGCTGCTGATCAGGTACTACGACAACG 6 1 2 0
L P G P T S A H I K Q L L I R Y Y D N G
77
•

•

•

•

•

•

GAGGCGGAAATCTTTCATATGACGGACAGAGAATCAATTTTGCTGCTATCATCACACCAC 6 1 8 0
G G N L S Y
D G Q R I N F A A I I T P P
97
•

•

•

•

*

•

CACACAACATGCTGAAGCAGCTGGCGAAGGTCACCTCCTCCACCTAGGCCAGACACTGAT 62 4 0
H N M L K Q L A K V T S S T *
111
TATATGGTTCATATGGGTAATTACCTTCCCTAGGCTAAGGACTAACTGGTATATACCATA 6 3 0 0
ATTAAAAAAAAAAA

6314

(Figure 2, confd)
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Figure 3: Schematic representation of the SHFV 3' ORFs as compared to the 3' ORFs
of the other arteriviruses. AO ORFs are drawn approximately to scale.
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These SHFV ORFs were numbered 2a, 2b, 3, 4, 5, 6, 7, 8 and 9 using conventional
nomenclature (Cavanagh, et al. 1990). ORFs 2a, 2b, 3 ,4 ,5 ,6 ,7 ,8 and 9 encode peptides of
281,204,205,214,179,182,278, 162 and 111 amino acids in length, respectively (Fig. 2,
Table 2). The smallest ORF is ORF 9 which encodes a peptide of approximately 12.3 kDa
and the largest ORF is ORF 2a which encodes a peptide with a mass o f 31.8 kDa. ORF 7
encodes the second largest peptide of 31.3 kDa. The remaining ORFs encode peptides
between 17.8 and 24.1 kDa (Table 2). All of the ORFs encode neutral to basic peptides with
estimated pi values at pH 7.0 between 6.2 and 11.7. With the exceptions of ORFs 4 and 7,
each of the SHFV 3’ ORFs overlap their adjacent 5' ORFs (Table 2). A unique feature of the
SHFV genome is that ORF 2a overlaps ORF lb by 41 nucleotides; there is no overlap
between ORFs lb and the adjacent ORFs 2 in the other arterivirus genomes. Each ORF
contains

at least one potential N-linked glycosylation site (Fig. 2, Table 2). The ORF 2b and

7 peptides contain the most N-linked glycosylation sites with 10 and 8, respectively. Four
of the 3' ORFs encode peptides containing only one or two potential N-linked glycosylation
sites (Table 2).
3.2 Identification of the sgRNAs synthesized daring replication.
Northern blot analysis o f RNA extracted from SHFV-infected cells detected six
polyadenylated virus-specific sgRNAs, with estimated lengths of 4.7, 3.3,2.7,2.0,1.2 and
0.65 kb (Godeny, et al., 1995; Zeng, et al., 1995). However, since SHFV encodes nine ORFs
at the 3' end of the genome and the arteriviruses are not known to translate more than one
ORF from each sgRNA, nine sgRNAs should be produced during SHFV replication.
Therefore, RT-PCR, which is a more sensitive method than Northern blot analysis, was used
to identify the number of sgRNAs produced during replication and to map each of the leader-
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Table 2. Characteristics of the sgRNAs and the corresponding ORFs encoded at the 3' end of the SHFV genome

ORF

sgRNA
Length (kb)

ORF
ORF
Amino
Length (nt) Overlap (nt)* Acids

Peptide
Mass (kDa)

Pi

Glycosylation
Sites
Identity

2a

5.049

843

41

281

31.8

10 . 2

1

9•

2b

5.049

612

310

204

22.7

6.7

10

9•

3

4.032

615

160

205

23.1

6.2

4

9•

4

3.454

642

-42

214

24.1

9.5

2

9•

5

2.827

537

148

179

19.1

6.2

6

?

6

2.642

546

175

1 82

19.6

7.5

4

9•

7

1.921

834

- 5

278

31.3

8.2

8

9
•

8

1.210

486

4

162

17.8

11.3

2

p20

9

0.629

333

23

111

12.3

11.7

2

pl5

'Number of nucleotides the ORF overlaps the adjacent 5' ORF.
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body junction sites on the sgRNAs. Table 3 shows the reverse primer sequences used for the
RT-PCR reactions and the location of the primer sequences downstream o f the respective
ORF initiation codons. The forward primer used in the reactions was located within the
SHFV 5' leader sequence as described in Materials and Methods.
Although SHFV encodes nine ORFs at the 3' end of its genome, only eight SHFV
sgRNAjunction sequences were found (Fig. 4). These were located upstream of ORF 2a and
of ORFs 3 through 9. ORF2a and 2b appear to share the same junction sequence as the ORF
2a junction region was obtained when the ORF 2b primers were used. There is a junction
sequence located upstream of each of the remaining seven SHFV ORFs. The consensus
junction

sequence

among

the

sgRNAs is a

nananucleotide

sequence,

5’-

(U/CXC/LONCU/QCU/CXA/C/GjACCC/LO-S’, in which only the residues at position 7 and
8 are strictly conserved (Fig. 4). The distance between the junction sequence and the
initiation codon for the respective ORF varies from 1 nt (ORF 5) to 177 nts (ORF 6).
Based on these results, it is assumed that SHFV produces eight sgRNA species during
replication (Fig. 5). Using conventional nomenclature (Cavanagh et al., 1990), these sgRNAs
were designated RNAs 2 through 9 with calculated lengths o f 5.049,4.032, 3.454, 2.827,
2.642,1.921,1.210 and 0.629 kb, respectively. These size estimates exclude the 3’ poly(A)
tail but include the 208 nt 5' leader sequence. With the exceptions of sgRNAs 3 and 5, these
RT-PCR-generated sgRNA lengths correspond to the estimated lengths generated by
Northern blot analysis (Godeny, et al., 1995; Zeng, et al., 1995) as shown in table 4.
33 Enumeration and characterization of the SHFV structural proteins.
It was previously reported that SHFV contains at least four major structural proteins
with apparent molecular masses of 15 (pi 5), 20 (p20), 38-46 (p42) and 48-60 (p54) kDa, as
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Table 3. Reverse primer sequences used for RT-PCR amplification of the SHFV
sgRNA junction sequences and the location of the primer sequence
downstream of the initiation codon.
Distance to
Initiation
Codon (nt)
263

ORF
2a

Reverse Primer Sequence
(5' -*• 3')
TTGAAACCCTTCTCTGCC

2b

GCAGATGAAAGCAAGCAAC

10 4

3

TTCGCCATAACCCAGAAC

282

4

AAAGAACTGGGTTCGCAC

338

5

GAAGTGCAACTTGACCTGAG

115

6

CGCAATCACAATGAACAAG

506

7

AAAGTCAAGAAAGGAGGCAG

490

8

GTCGCGTTAATCGCTAAAC

313

9

CATATGAAAGATTTCCGCC

231
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Figure 4: Identification of the SHFV sgRNA junction sequences. The sequences of the
sgRNA junction regions are compared to the SHFV genome sequence. The 5' leader
sequence, located at the 5' end of the SHFV genome, was determined previously (Zeng,
et aL, 1995) and is shown on the top line of each comparison. Viral genome sequences
upstream of each of the SHFV ORFs is shown on the bottom line of each comparison.
Genomic nucleotides in bold type contribute to the sgRNA sequence. Nucleotides
which are identical in both the sgRNA and genome sequences are identified with a
colon. Initiation codons are indicated in bold type and underlined. The overall
junction region consensus sequence is shown at the bottom of the figure with the most
common nucleotide represented in the middle line.
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5' L eader
ORF 2 a sgRNA
Genome

5'
5'
5'

.ADDDGCAGACCCPCCPPAACCAPGPPCPGPGAGPGCCCPCG. . . 3 '

5' L ead er
ORF 3 sgRNA
Genome

5'
5'
5'

.AOUUGCAGACCCUCCUUAACCAOGUOCUGUGAGUGCCCUCG. . . 3'
. AUTOGC^GACCCUCCUOCACCCUGAACUCUO- 4 5 n t - ACJG. . . 3 '

5' L eader
ORF 4 sgRNA

5'
5'

. ADOPGCAGACCCOCCPPAACCAPGPPCPGPGAGPGCCCPCG. . . 3'
. APUPGCAgACCc 6 c c 6 6 a ACCAAAPACCOAC-1 2 4 n t -APG. . . 3 '

Genome

5'

.AOCCUAGGAOOOCDAdOAACCAAAOACCaAC^iiint-^S- • - 3 '

5' L eader
ORF 5 sgRNA
Genome

5'
5'
5'

.ADOOGCAGACCCPCCPPAACCAPGPPCPGPGAGPGCCCPCG.
. . 3'
• • • • • • » • • • • • • •
• • • • •
• • •
• • •
•
. AOOPGCAGACCCOCACPAACCCAOGGAUGUCCGOGGOCCUC. . . 3 '

5' L eader
ORF 6 sgRNA

5'
5'

Genome

5'

. ADDUGCAGACCCUCCUDAACCAUGUUCUGUGAGUGCCCUCG.
. . 3'
• • • • • • • • » • • • • • • • •
• • • •
•
. APaPGCAGACCCPCCP6GACCAAAACAaAGA-168nt-APG. . . 3 '
. GPGGCARCGPPGPCAPUGACCAAAACADAGA-i68n-t-AUGl I I 3 '

5' L eader
ORF 7 sgRNA

5'
5'

.ADDUGCAGACCCPCCPPAACCAPGPPCPGPGAGPGCCCPCG. . . 3'
. Ao p p g c a g a c c c p c c p p a Ac p Ac c p a a p p a u g p a c p p a p g p . . . 3 '

Genome

5'

. g c g c g a c pc c g c pc c ppa a c 6 a cc 6 aad 6 apg 6 a c p p a p g p I 11 3 '

5' L eader
ORF 8 sgRNA

5'
5'

. APPPGCAGACCCPCCPPAACCAPGUUCPGUGAGUGCCCUCG.
. . 3'
• • • • • • • • • • • « • • • •
• • • • •
•

Genome

5'

. APPPGCAGACCCPCCPCAACCACGACGACGP—117 n t - fiJ2£ • • • 3 '
.GAGGPAGAPPAPPPGPCAACCACGACGACGP-ii7nt-ifflSl ! I 3 '

5' L eader
ORF 9 sgRNA

5'
5'

. APUOGCAGACCCPCCPPAACCAPGPPCPGPGAGPGCCCPCG. . . 3 '
. APPPGCAGACCCPCCPPAACCPGAGGAAGPAPGGCPGGCAA. . . 3 '

Genome

5'

. CCAAAAGGGGPCPPGPPAACCPGAGGAAGDAPGGCPGGCAA.I I I 3 '

C o n sen su s

. APPPGCAGACCCPCCPPAACPPCPGPPPCAC— 7 7 n t -AUG. . . 3 '
. COCUAGCCAAGGOCUOUAACUUCUGOOOCAC-' 7 7 n t - £ 2 £ - ”

•

•

»

•

•

»

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

3'

•

. UAGCUGCCUUAACCOUdCACCCUGAACUCTU- ’ 4 5 n t - AUG I "

3'

. CGCACAGDDADCDCACnAACCCADGGAPGPCCGPGGPCCPC! ! ! 3 '

5'

C P CCC
P
-U C N U U A A C C - 3 '
G

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

56

Figure 5: Schematic representation of the SHFV sgRNAs produced during virus
replication. The deduced sgRNAs and die ORFs translated from each RNA species are
shown. ORFs are indicated by gray boxes and die 5' leader sequences are depicted by
white boxes. Solid lines represent untranslated RNA. The lengths of the sgRNAs are
shown to the right of each RNA. ORFs and RNAs are drawn approximately to scale.
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Table 4. Comparison of RT-PCR and Northern Blot analysis for the detection of
SHFV sgRNAs

ORF

ORF
Length (kb)

sgRNA
Length (kb)

Northern Blot*
Estimated Size (kb)

2a

843

5.049

4.7

2b

612

5.049

3

615

4.032

4.7
?

4

642

3.454

5

537

2.827

3.3
?

6

546

2.642

2.7

7

834

1.921

2.0

8

486

1.210

1.2

9

333

0.629

0.65

“Results from Godeny, et al. (1995) and Zeng et al. (1995)
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measured by SDS-PAGE analysis (Godeny and Brinton, 1992; Godeny, et al., 1995).
Because the p42 and p54 glycoprotein bands migrate as very broad bands by polyacrylamide
gel electrophoresis, the exact number of glycoproteins in the SHFV virion particle has not
been fully determined. Therefore, attempts were made to determine the number of individual
viral glycoproteins within the p42 and p54 bands.
Metabolically-radiolabeled SHFV particles were treated with endoglycosidase F,
which cleaves both the asparagine-linked high-mannose and complex glycans from the
glycoprotein peptide backbone (Winkler, et al., 1987). The resulting SHFV peptides were
then separated by SDS-PAGE. As shown in figure 6, lane A, four major structural proteins
are observed with untreated SHFV particles, p i5, p20, p42 and p54. No peptides were
detected in mock-infected cell samples (lane B). Interestingly, treatment of the SHF viral
particles with endoglycosidase F resulted in the disappearance of the p42 and p54 bands and
the emergence of four new bands with molecular masses between 28 and 30 kDa (Fig. 6, lane
C). Two additional bands appeared at 16 and 22 kDa (lane C); however, these may be the
digestion products of the peptides which migrate at 27 and 33 kDa (lane A). These peptides
are occasionally observed in SDS-PAGE-separated SHFV samples but have not been
determined to be viral in origin (Godeny, et al., 1995).
Further, Western blot analysis using anti-SHFV polyclonal antisera made in African
green monkeys support the radiolabeled protein data. As shown in figure 7, pl5, p20, p42
and p54 were all detected from intact SHFV particles by Western analysis (lane A).
Treatment of the virus with endoglycosidase F resulted in the detection of the four new
peptides, between 28 and 30 kDa and the lack of p42 and p54 detection with the anti-SHFV
serum (lane B). Taken together, the radiolabeled virus data and the Western analysis data
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Figure 6: Autoradiograph of l4C-amino acid-labeled SHFV structural proteins.
Proteins from purified, extracellular SHFV particles (lane A), media obtained from
mock-infected MA104 cells (lane B), and endoglycosidase F-treated, purified,
extracellular SHFV particles (lane Q were separated by SDS-PAGE. Lines with
numbers indicate the positions and molecular mass (kilodaltons) of standard proteins,
arrows indicate the SHFV structural proteins, and dots represent unique peptides
obtained after endoglycosidase F treatment.
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Figure 7: Western blot analysis of SHFV structural proteins treated (lane B) or
untreated (lane A) with endoglycosidase F. Viral proteins were separated by SDSPAGE. African green monkey anti-SHFV sera was used as the primary antibody for
the Western analysis. Lines with numbers at the left of die figure indicate the positions
and molecular mass (kilodaltons) of standard proteins; whereas lines on the right
indicate the SHFV structural proteins. Arrows represent unique peptides obtained
after endoglycosidase F treatment.
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suggest that the SHFV p54 and p42 glycoprotein bands represent at least four viral
glycoproteins.
It had been shown that the capsid protein of EAV was phosphorylated (Zeegers, et
al., 1976). Therefore, attempts were made to determine if the SHFV capsid protein was a
phosphoprotein. Both EAV and SHFV particles were metabolically-radiolabeled with 32Pphosphate, separated by SDS-PAGE, and detected by autoradiography. A phosphoprotein
band was detected with a molecular mass of approximately 14 kDa (capsid protein) in the
EAV sample but no phosphorylation was detected in the SHFV preparation.
Further post-translational modification studies were performed. Many viral proteins
have been shown to be myristylated (reviewed in Towler, et al., 1988). Therefore, SHFV
particles were metabolically radiolabeled with 3H-myristic acid to determine if any of the
SHFV structural proteins were myristylated. Although we could not detect myristylation of
any of the SHFV structural proteins, a peptide with an approximate molecular mass of 6 kDa
(Vp4; Chow, et al., 1987) was myristylated in the coxsackievirus B3 control sample.
Together, these data suggest that the SHFV structural proteins are neither phosphorylated nor
myristylated.
3.4 Characteristics and identity of the SHFV ORF 7 gene product.
Since the SHFV ORFs 8 and 9 were identified as the capsid and membrane protein
genes, respectively, it was of interest to map one of the large envelope glycoprotein genes
on the SHFV genome. It was previously shown that the large envelope glycoprotein genes
of EAV, LDV and PRRSV were mapped to ORF 5 on the respective genomes (de Vries, et
al., 1992; Faaberg and Plagemann, 1995; Meulenberg, et al., 1995). Since ORF 5 of these
viruses is the third ORF from the 3 ' end of the genome, the corresponding ORF in SHFV,
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ORF 7, was examined to determine if it also encoded one of the SHFV large envelope
glycoproteins. It should be noted that the SHFV ORF 7 gene encodes a peptide with eight
potential N-linked glycosylation sites (Table 2).
A hydrophobicity plot was performed on the peptide encoded by the SHFV ORF 7
gene using the method of Kyte and Doolittle (1982). As shown in figure 8, there is a
hydrophobic region toward the middle of this peptide spanning amino acids 140 through 204.
Three peak hydrophobic domains are observed within this region. The carboxy terminal end
of this peptide shows hydrophobic domains interspaced with hydrophilic regions; whereas,
the amino terminus is more hydrophilic than hydrophobic (Fig. 8).
The SHFV ORF 7 hydrophobicity plot is similar to plots generated for the ORF 5
products of EAV, LDV, and both the American and European isolates of PRRSV (Fig. 8):
all five peptides contain a hydrophobic region toward the center of the sequence; the carboxy
terminus contains both hydrophilic and hydrophobic regions; and the amino terminal ends

of the peptides are more hydrophilic than hydrophobic. Further, computer analysis of the
SHFV ORF 7 peptide sequence and the amino acid sequences of the ORF 5 products of LDV
and PRRSV/LV using the GAP program within the GCG software package shows 53% and
57% sequence similarity, respectively. These data suggest that the peptide encoded by the
SHFV ORF 7 may be similar to the products of the ORF 5 genes of the other arteriviruses.
To further identify the SHFV ORF 7 gene product, the gene was cloned and
expressed. The ORF 7 gene was amplified by RT-PCR and the amplified product was
separated by electrophoresis through an agarose gel as described in Materials and Methods.
As shown in figure 9, a polynucleotide product of approximately 950 nucleotides was
obtained by these methods. After cloning and sequencing this ORF 7 product, it was
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Figure 8: Hydrophobicity plot for the SHFV ORF 7 peptide as compared to the
hydrophobicity plots of the EAV, LDV, and PRRSV ORF 5 peptides. PRRSV/LV and
PRRSV/VR-2332 are the European and American PRRS viruses, respectively.
Hydrophobicity was determined as described by Kyte and Doolittle (1982) using the
GCG PeptideStructure program.
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Figure 9: Ethidium bromide staining of the SHFV ORF 7 RT-PCR product after
electrophoresis through a 1% agarose geL Lane + indicates that SHFV genomic RNA
was added to the RT-PCR reaction, while lane - indicates that the RT-PCR reaction
was performed without the viral RNA. The lines and numbers refer to the positions of
standard DNAs and their lengths (kilo bases).
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determined that the amplified product was 870 nucleotides in length and contained the
identical ORF 7 sequence as shown in figure 2.
In order to express the ORF 7 product in-vitro, it was first necessary to transcribe
RNA from the cloned ORF 7 gene. Sequencing showed that the ORF 7 gene was oriented
within the pCR plasmid vector under the control of the T7 promoter. Therefore, ORF 7 RNA
was transcribed using T7 polymerase as described in Materials and Methods. Because the
amount o f translation product derived from capped and uncapped mRNAs can differ
depending on the gene being expressed, both capped and uncapped ORF 7 RNAs were
transcribed (Fig. 10). The uncapped RNA migrated as a polynucleotide approximately 900
nucleotides in length (lane A) while the capped RNA migrated a little slower (lane C). No
RNA was transcribed in the control reactions (lanes B and D). It also appeared that the
uncapped RNA was transcribed at a slightly higher concentration than the capped RNA.
The transcribed ORF 7 mRNA was next used as template for in-vitro translation of
the ORF 7 product For the remainder of this study only the uncapped transcription product
was used because no difference was observed in the amount of product translated from the
capped or uncapped mRNA. Both the rabbit reticulocyte lysate and wheat germ extract
systems were used for the in-vitro translation of the ORF 7 product As shown in figure 11,
a single protein product with a molecular mass of about 31 kDa was observed using the
wheat germ extract system (lane B). This mass corresponds to the predicted coding capacity
of the SHFV ORF 7 gene. No product was translated using the wheat germ extract system
without mRNA added (lane A) or the rabbit reticulocyte lysate system with (lane D) or
without (lane C) ORF 7 mRNA. Although this experiment showed that the SHF ORF 7 gene
could be expressed in-vitro, the results were disappointing.

Since the next step in
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Figure 10: Ethidium bromide-stained, agarose gel-separated, in vitro transcription
products of the SHFV ORF 7 cDNA. The uncapped mRNA product is seen in lane A;
whereas the capped mRNA product is shown in lane C. As negative controls, the ORF
7 cDNA was removed from the uncapped and capped reactions, lanes B and D
respectively. The lines and numbers indicate the positions of standard RNA markers
and their lengths (kilobases).
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Figure 11: Autoradiographic comparison of the wheat germ extract and rabbit
reticulocyte lysate systems for the in vitro translation of the SHFV ORF 7. Products
from the wheat germ extract reactions are shown in lanes A and B, and lanes C and D
contain the products from the rabbit reticulocyte lysate reactions. ORF 7 mRNA was
removed from the reactions to serve as negative controls (lanes A and C). Lines and
numbers indicate the position and molecular mass (kilodaltons) of protein standards.
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showing that this ORF encodes a viral glycoprotein was to express the product as a
glycoprotein and the rabbit reticulocyte lysate system is the only in-vitro glycoprotein
expression system available, it was necessary to express the peptide in the rabbit system.
Because the protein product was made using the wheat germ extract system, it was possible
that the ion concentrations in the rabbit reticulocyte lysate kit were not optimal. Therefore,
the ORF 7 mRNA was next expressed using the Flexi rabbit reticulocyte lysate kit which
allows for the optimization of ion concentrations. It was found that the elimination of Mg4-"
and altering the KC1 concentration in the rabbit reticulocyte lysate reaction resulted in the
production of the ORF 731 kDa peptide (Fig. 12, lane A). Optimal KC1 concentration in the
reaction was determined to be 3.0 mM.
Canine pancreatic microsomal membranes were added to the Flexi rabbit reticulocyte

reaction mixture in order to determine if the SHFV ORF 7 product was a glycoprotein.
Addition of these microsomal membranes shifted the molecular weight o f the ORF 7 product
from 31,000 to approximately 52,000 (Fig. 12, lane B), suggesting that ORF 7 encodes a
viral glycoprotein. This molecular weight range coincides with the SHFV p54 glycoprotein.
Similar to pS4, the 52 kDa glycoprotein also migrated on SDS-PAGE as a wide band.
To confirm that the 52 kDa ORF 7 product was a glycoprotein, the in vitro translation
product was treated with endoglycosidase F to remove the carbohydrate residues. As
expected, this treatment had no effect on the size of the ORF 7 product synthesized in the
absence of microsomal membranes. In contrast, endoglycosidase F treatment of the 52 kDa
glycoprotein resulted in a shift in the molecular weight of the peptide to approximately
29,000 (Fig. 12, lane C). Surprisingly, this molecular weight is smaller than the ORF 7
product synthesized in the absence of microsomal membranes (31,000), suggesting that a
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Figure 12: Autoradiograph of SDS-PAGE-separated, in vitro translation products of
the SHFV ORF 7 gene using the Flexi rabbit reticulocyte lysate system. The in vitro
translation reactions were performed with (lanes B and C) or without (lane A) the
addition of canine pancreatic microsomal membranes. Lane C shows the glycosylated
ORF 7 product after digestion with endoglycosidase F. Lines and numbers indicate
positions and molecular masses (kilodaltons) of protein standards. Arrows point to the
ORF 7 products.
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signal sequence of approximately 2 kDa was cleaved from the peptide during glycoprotein
synthesis. It is noteworthy that the 52 kDa ORF 7 product and its cleavage product, 29 kDa,
correspond to the SHFV p54 and one of its potential cleavage products, 28-30 kDa (Fig. 7),
suggesting that ORF 7 may encode one of the p54 glycoproteins.
In order to determine the identity of the SHFV ORF 7 product, anti-SHFV sera was
needed. Therefore, two antisera directed against SHFV proteins were produced: polyclonal
monkey antiserum against whole virus particles and monospecific mouse antiserum against
the ORF 7 product
Polyclonal anti-SHFV serum was made in African green monkeys using gradient
purified whole virus as described in Materials and Methods. Serum was obtained from the
monkeys and a dilution curve using ELISA with whole virus particle proteins as antigen was
determined (Fig. 13). Using a 50% reduction in the maximum O.D. obtained by ELISA as
endpoint the antisera exhibited an ELISA titer of 5,000. Normal African green monkey
serum did not specifically react to.the SHFV antigens. As expected, this antisera reacted to
all of the known SHFV structural proteins (Fig. 7).
Monospecific, polyclonal anti-SHFV ORF 7 product serum was made in mice. As
described in Materials and Methods, the ORF 7 gene was removed from the pCR 2.1 vector
and placed under the cytomegalovirus promoter within the pcDNA 3.1 plasmid vector. The
pcDNA-ORF 7 plasmid was used for genetic immunizations of BALB/c mice. Serum was
obtained from these mice and assayed by ELISA using proteins from gradient-purified SHFV
as antigen. The dilution curve of the murine serum is shown in figure 14. The anti-ORF 7
serum exhibited a titer o f800 when assayed against the SHF virus particle proteins; normal
BALB/c mouse sera did not specifically react with these antigens. Since the anti-ORF 7
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Figure 13: Dilution curve of polyclonal African green monkey anti-SHFV sera as
assessed by ELISA using viral structural proteins as antigen. The solid curve
represents the anti-SHFV sera while the dotted curve represents normal monkey sera.
All dilutions were performed in triplicate. Dots depict the mean value for each dilution
and the standard deviation is shown.
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Figure 14: Dilution curve of monospecific murine anti-SHFV ORF 7 sera as assessed
by ELISA using viral structural proteins as antigen. The solid curve represents the
anti-ORF 7 sera while the dotted curve represents normal murine sera. All dilutions
were performed in triplicate. Dots depict the mean value for each dilution and the
standard deviation is shown.
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serum reacted to proteins from purified SHFV particles, the ORF 7 product must be a viral
structural protein.
To further investigate whether the ORF 7 gene encodes one of the SHFV p54
glycoproteins, immunoprecipitation studies were performed using the monospecific murine
anti-SHFV ORF 7 serum. When intact SHFV particles where used as antigen, all of the
known SHFV structural proteins were immunoprecipitated out of the mixture (Fig. 15, lane
A), suggesting that the ORF 7 product is found on the outer surface of the viral envelope.
As expected, this antisera also immunoprecipitated both the nonglycosylated and
glycosylated forms o f the in-vitro expressed ORF 7 product (lanes C and D, respectively).
This antisera did not react with proteins from mock-infected cell supernatants (lane B) nor
the in-vitro translation reaction mixture without mRNA (lane E). Note that the glycosylated
form of the ORF 7 product migrates with the SHFV p54 protein band (Fig. 15, lanes A and
D).
Thus far, the data suggests that the ORF 7 gene encodes one o f the large envelope
glycoproteins, p54, of SHFV. To determine if anti-SHFV sera from other monkey species
could recognize the ORF 7 product, antisera from naturally infected patas and rhesus
monkeys were obtained from P. Jahrling (USAMRIID). Reactivity of this sera with SHFV
proteins and ORF 7 products were determined by ELISA and is reported in Table 5. All of
the monkey anti-SHFV sera reacted against SHFV proteins and both the glycosylated and
nonglycosylated forms of the ORF 7 product; however, they did not react to proteins from
mock-infected cell extracts nor to rabbit reticulocyte lysate proteins. As expected, the
monospecific murine serum reacted to the same antigens as the monkey antisera (Table 5).

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

84

Figure 15: Autoradiograph of immunoprecipitated, SDS-PAGE-separated samples
using monospecific murine anti-SHFV ORF 7 sera. This antisera was used to
immunoprecipitate intact SHFV particles (lane A), proteins from mock-infected MAI04
cell supernatants (lane B), in vitro expressed ORF 7 products made in the presence
(laneD) and absence (lane C) of microsomal membranes, and proteins from them vitro
translation reaction without the addition o f SHFV RNA (lane E). Lines and numbers
indicate the positions and molecular masses of protein standards (kilodaltons).
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Table S. ELISA values* using anti-SHFV serabfrom various monkey species or from genetically- immunized mice* against
native SHFV proteins or in vitro expressed ORF 7 products
Anti-SHFV
African green
monkey sera

Normal
African green
monkey sera

Anti-SHFV
patas
monkey sera

Anti-SHFV
rhesus
monkey sera

Anti-ORF 7
murine
sera

Normal
murine
sera

SHFV

0.684

0.059

1.122

1.084

0.277

0.083

MA104
cell extracts

0.093

0.065

0.085

0.078

0.120

0.078

ORF 7 glyco
sylated product

0.304

0.071

0.560

0.528

0.405

0.087

ORF 7 nonglyco
sylated product

0.327

0.059

0.509

0.497

0.451

0.072

rabbit reticulo
cyte lysate

0.097

0.090

0.081

0.095

0.170

0.067

“ELISA values are expressed as O.D.4S0.
bAU monkey sera was diluted 1:5000 and all murine sera was diluted 1:800.
cMice were genetically-immunized with the SHFV ORF 7 gene.
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Since antibodies directed against the large envelope glycoproteins of the other
arteriviruses can neutralize the respective viruses, it is expected that if the ORF 7 gene
encodes one of the SHFV large envelope glycoproteins, then antisera against this
glycoprotein should neutralize virus infectivity. Therefore, the monospecific murine antiORF 7 peptide sera was assayed for virus neutralization activity by the plaque inhibition
assay. As expected, this antisera did exhibit neutralization activity with a titer of 80.
Taken together all of the above data suggests that the SHFV ORF 7 gene encodes one
of the viral large envelope glycoproteins. This data is consistent with those of the other
arteriviruses in which the third ORF from the 3' end of the genomes were identified as the
respective large envelope glycoprotein genes.
3.5 Determination of the number of antigenic epitopes on the SHFV large envelope
glycoprotein.
In order to determine the antigenic epitopes found on the SHFV large envelope
glycoprotein it was necessary to produce monoclonal antibodies against the glycoprotein.
Therefore, initial attempts involved inoculating mice with proteins from whole virus
particles. After three inoculations of viral proteins, antiviral activity was detected in the
mouse sera. Hybridomas were synthesized from the splenic cells of these mice, as described
in Materials and Methods. mAbs produced by the hybridomas were screened by ELISA to
detect SHFV reactivity; those determined to be positive were then screened by Western
analysis to determine viral protein specificity. As shown in Table 6, eleven hybridomas were
found and cloned. All of these hybridomas produced mAbs against the capsid, pl5, protein.
Hybridomas producing mAbs directed against the viral envelope proteins were not identified.
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Table 6. ELISA values of supernatant fluids from hybridomas* producing mAbs to
SHFV and identification of the viral protein(s) to which the mAbs are
directed.

mAb

ELISA
valueb

11D3
11F3
11F6
12H7
13A8
14A9
14E6
14E1
14F2
15C5
22F10
23C8

Over**
Over
0.633
0.899
0.793
1.201
0.957
0.226
0.568
0.220
0.198
Over

Viral Protein
Directed Against*
pl5
pl5
pl5
pl5
pl5
pl5
pl5
pl5
pl5
pl5
pl5
pl5

‘Hybridomas were produced from mice immunized with purified SHFV particles.
'’ELISA values (O.D.450) were determined using undiluted supernatant fluid from hybridoma
cultures.
T he protein the mAb was directed against was determined by Western Blot analysis.
dOver, O.D.4J0 * 2.0
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These data are not surprising, as the SHFV capsid protein appears to have the highest copy
number of all the structural proteins in the virus particle.
Further investigations were needed to produce mAbs against the SHFV large
envelope glycoprotein, p54. Since ORF 7 was identified as one of the p54 genes and
polyclonal antiserum against the ORF 7 product was produced in mice using genetic
immunizations, attempts were made to produce mAbs against the large envelope
glycoprotein using genetic immunization of mice. Although anti-p54 serum was produced
in these mice, initial attempts to produce mAb-producing hybridomas failed. Success was
achieved, however, by i m m u n i z i n g the mice with SHFV proteins two weeks after the last
genetic i m m u n i z a t i o n boost. Hybridomas were screened by ELISA using whole virus protein
initially followed by ORF 7 product alone. Using these methods, eight hybridomas
producing mAbs against p54 were identified and cloned. These hybridomas were numbered
p5F3-26, p6F7-6, pi 1C4-5, pl5F3-12, pl6A8-l 1, pl6F7-25, p33Dl-7 and p35F10-l. The
mAbs produced by these hybridomas were isotyped (Table 7). It was determined that five
of the eight hybridomas produced IgM antibodies. The antibodies produced by p5F3-26,
pl6A8-l 1 and pl6F7-25 were IgGl, IgG2a and IgG3, respectively. Only kappa light chains
were detected in the mAbs; none of the mAbs exhibited lambda light chains (Table 7).
In order to determine the number of antigenic epitopes on the p54 glycoprotein,
competitive binding assays were performed using the anti-p54 mAbs. A first mAb was
bound to SHFV proteins from purified virus particles. A second mAb, which was labeled
with biotin was then allowed to bind to the viral proteins. Should both antibodies recognize
the same antigenic or related epitope, then the first antibody will block the binding of the
biotinylated antibody. ELISAs were performed to determine the amount of second antibody
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Table 7. Immunoglobulin isotyping of anti-p54 specific mAbs*

IgA
p5F3-26
pllC4-5
pl5F3-12
pl6A 8-ll
pl6F7-25
p6F7-6
p35F10-l
p33Dl-7

IeM
—

Isotype
IfiGl IgG2a IgG2b IgG3
+

—

—

—

—

—

—

—

—

+
+

—

—

—

—

—

—

—

+

—

—

—

—

—

+

—

—

—

—

—

—

+
+

—

—

—

—

—

+

—

—

—

—

K

X

+
+
+
+
+
+
+
+

aAnti-p54 mA )s were generated from hybridomas produced from mice geneticallyimmunized with the SHFV ORF 7 gene.
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binding. As shown in Table 8, at least four epitopes could be delineated using this method.
mAbs pi 1C4-5, p33Dl-7 and p35F10-l defined one epitope, p5F3-12 and p6F7-6 defined
a second epitope and pl5F3-26 and pl6F7-25 defined a third epitope. pl6A 8-l 1 was the
only mAb to bind to a fourth epitope. None o f the mAbs completely inhibited the binding
of the second antibody, even if both antibodies were the same (Table 8). Competitive
inhibition in this assay was defined as positive if the % Blocking Ability was greater than
40%. All the negative values in this assay were 15% or lower (Table 8). It is not possible
to unequivocally state that the blocking of binding of one antibody by another antibody is due
to their recognizing the same epitope. It is possible that they recognize adjacent epitopes and
that blockage o f binding is due to steric hindrance. Therefore, this study shows that at least
four antigenic epitopes were identified in the p54 glycoprotein.
Since the arteriviral GLglycoproteins are known to posses the virus neutralization
sites, the anti-ORF 7 peptide mAbs were assayed for virus neutralization activity.
Supernatant fluids containing one mAb directed against each of the four antigenic epitopes
was used for this assay. Virus neutralizing activity was detected with neat supernatant fluid
containing mAb p6F7-6. None of the other mAbs exhibited virus neutralization activity.
These data suggest that the antigenic epitope as defined by mAbs p6F7-6 and p5F3-12 is a
virus neutralization site.
3.6 Comparison of the ORF 7 gene sequence among different SHFV isolates.
Because the SHFV ORF 7 gene was shown to encode one of the viral large envelope
glycoproteins and that this molecule contains at least four antigenic epitopes, the similarities/
differences in this gene sequence among different SHFV isolates was next determined. The
genome sequence shown in figure 2 was derived from the prototype SHF virus, LVR, which
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Table 8. Competitive binding* of the anti-p54 mAbs
Biotinylated 2° mAb
1° rnAb

PI1C4-S

P33D1-7 p3SF10-l pSF3-12 p6F7-6 p!5F3-26 p!6F7-2S p !6 A 8 -ll

pllC4-5

59b

42

68

0

9

3

2

0

p33Dl-7

44

79

61

10

0

11

5

15

p35F10-l

54

45

58

1

0

7

3

0

p5F3-12

12

0

0

55

63

6

0

0

p6F7-6

0

0

0

47

63

0

11

0

pl5F3-26

8

0

0

8

0

65

52

8

pl6F7-25

0

0

0

2

3

48

64

9

p!6A 8-ll

6

13

0

0

4

4

7

53

"Competitive binding was assessed by binding concentrated 1° mAb to 0.05 |ig of purified
SHFV proteins followed by the binding of the biotinylated 2 ° mAb. Binding of the 2 ° mAb
was determined as O.D.4S0.
bCompetitive binding values are expressed as % Blocking Ability (see Materials and
Methods)
Outlined box defines neutralizing epitope.
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was isolated from an NIH outbreak in 1964. Two additional virus isolates were available in
the laboratory which were isolated from the 1989 New Mexico outbreak: one virus was
isolated from a rhesus monkey and the second virus was isolated from a mouse. The ORF
7 sequence of these New Mexico isolates were cloned, sequenced and compared to the LVR
sequence. Since these isolates were separated from the prototype isolate by over 2,000 miles
and 25 years, it was expected that the ORF 7 sequence would differ from the earlier
sequence. Also, the glycoprotein encoded by this gene is exposed on the surface of the virus
particle and should be under im m unological stress which could result in mutations.
Surprisingly, the ORF 7 gene from the New Mexico isolates was identical to the ORF 7 gene
of the prototype isolate (Fig. 16). Interestingly, although no sequence difference was
observed among different isolates, two nucleotide changes resulted in this gene by passing
the virus through a primary rhesus monkey macrophage culture: position 31, C to T and
position 243, T to C. The change at position 31 results in an amino acid substitution in the
peptide from proline to a serine residue; the nucleotide change at position 243 is a silent
mutation. Although a mutation resulting in a serine substitution for proline seems important,
computer analysis of the glycoprotein suggests that this substitution would be within the
signal sequence of the glycoprotein (Wisconsin Package Version 9.0, Genetics Computer
Group (GCG), Madison, WI). Since signal sequences are cleaved from glycoproteins during
synthesis, this substitution should not effect the confirmation of the viral glycoprotein.
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Figure 16: Comparison of the ORF 7 gene sequences from different SHFV isolates.
LVR is the prototype SHFV isolate which was propagated in MAI04 cells. LVR/MAC
is the prototype isolate passaged once in primary rhesus monkey macrophage cultures.
The other two isolates were obtained from the 1989 SHFV outbreak in New Mexico.
PH0080 was derived from a splenic homogenate from a rhesus monkey and 1-621 was
isolated from the liver of a rhesus monkey after experimental inoculation of liver
homogenate from a mouse trapped during the outbreak. Dashed lines represent
nucleotide identity between the prototype and the other isolates.
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LVR:

5'
A TG TA CTTA TG TTTA G G G A G A TCG G A G A CTCCG TTG A TA G G TTTG TTCCG

1 -6 2 1 :
PH 0080:
LVR/MAC:

----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------T ---------------------------------------•

•

•

•

50

•

CACCTCATCTACATCTATCTCATGGTTCTATGTGCTTTTCTTTGTCTCTA

100

TTACATTCAGCAGCACCGGCGCATCCGAGAACAACACCGGTACGACCTGG

150

ATCAGCATATCAAAGTTTCCGTCATTGCTGCTGAGTCAGATCATAAGCCC

200

TAGTTACATTGTAAATATCTCTGTCTGTGGTGCATTTGACATTCAAAATA

250

ACACTCACTGGTTCACTCCTTGTAATTTGTCTGTCTTGAATCACTCTGAC

300

TGTCACACGTGTAAGTCAGAGCAGTCAAACCAATCTTTATTATCAAATTG

350

TTCAACGTGTTTCACACACCTTAGTTCTTGTTTTCTTCACACTTACACTG

400

(Figure 16, cont'd)
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GACACCACATCAATAACACTAGGCTTCTTTTAGAGACATATTTAGCAGTC

450

CCCTTACTAACCCATTTATTGAGTTATAAGTTTGCTACAACTGCCTCCTT

500

TCTTGACTTTGCCTTTTTTGCAGGACTTTCTATTACGGCCTATCGCTATG

550

TTTCACCGGCGATATTATTCTTCTTGCCACTCGCTCTCATCTTCTCGGCT

600

ATCTTCATCAAGAAGTTAGTGGTAAATTGTATGGCCCTCCGCTTCGCGTG

650

GACTAGGCACACCAATTTCATCATTGACGACCGAGGTAGATTATTTGTCA

700

ACCACGACGACGTGCTGATTTCCGACCCACAGGGACTGCGGGTTGGACCT

750

CATAAGGTCAGAGCCGCTAAGGTAATACTTGGTGGACGGGAGGCAAATTT

800

3'
ACTCAGACAAGCACACGTCGAAGAGTGGTCATGGTAG

837

(Figure 16, cont’d)
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4.

DISCUSSION

SHFV is a member of the virus family Arteriviridae within the newly formed virus
order Nidovirales. This virus family contains only one genus, Arterivirus, which along with
SHFV includes EAV, LDV, and PRRSV. The order Nidovirales includes a second virus
family, the Coronaviridae. Members of the order Nidovirales share common genome
organizations and replication strategies. Both phylogenetic analysis of individual conserved
domains and comparison of genome organization strongly suggest that the arteriviruses and

coronaviruses comprise a distinct evolutionary lineage among positive-strand RNA viruses.
Unique features of this virus lineage are the location of the helicase domain on the Cterminal side of the polymerase domain and the presence of a conserved domain 4 in the
ORF lb polyprotein. A less significant but characteristic feature is the presence of -SDDsequence in place of the universal -GDD- signature sequence within the RNA-dependent
RNA polymerase domain (Snijder and Spaan, 1995).
Morphologically, the arteriviruses differ markedly from the coronaviruses. First,
coronaviruses gained their name from the large spike-like peplomers which protrude from
the virion surface; these spike proteins were visualized by electron microscopy and were said
to give the virus a “crown-like” or “corona” appearance (McIntosh, 1974). Spike-like
structures are not visible on the arterivirus virions; instead, cup-like subunits have been
observed (Brinton-Damell and Plagemann, 1975; Trousdale, et al., 1975). Second, the
diameters of the arterivirus particles are approximately half that of the coronaviruses (Snijder
and Spaan, 1995). Third, the nucleocapsids o f the arteriviruses are icosahedral, while those
of the coronaviruses are helical.
97
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Among the four arteriviruses, the molecular characteristics of SHFV are the least
known. In this report, the 3' end of the genome from the prototype isolate o f SHFV was
cloned and sequenced. This sequence contains the 76 nt 3' noncoding region, all of the 3'
ORFs and 1,590 nt o f the SHFV ORF lb gene. Combining these sequence data with the
SHFV ORF la/ lb sequence data obtained by M A Brinton (unpublished data; Georgia State
University, Atlanta, GA), the entire SHFV genome is estimated to be 15.7 kb in length.
Thus, the SHFV genome is longer than the genomes o f the other arteriviruses: 12.7 kb for
EAV (den Boon, et al., 1991a), 14.2 kb for LDV (Godeny, et al., 1993), and 15.1 kb for
PRRSV (Meulenberg, et al., 1993b).
The SHFV 3' ORFs were identified as ORFs 2a, 2b, 3,4, 5, 6,7, 8, and 9 moving
from the 5' end to the 3' end and using conventional nomenclature (Cavanagh, et al., 1990).
Perhaps the most striking feature of the SHFV genome sequence is the presence of three
additional 3' ORFs; the SHFV genome contains nine 3' ORFs, whereas the genomes of
EAV, LDV, and PRRSV contain six 3' ORFs. The ultimate and penultimate 3' ORFs
encode the capsid and membrane proteins, respectively (de Vries, et al., 1992; Godeny, et al.,
1990; Meulenberg, et al., 1995). Similarly, the corresponding SHFV ORFs (ORFs 9 and 8)
encode the same viral proteins (Godeny, et al., 1995). For EAV and LDV, ORFs 2 and 5
have been shown to encode the small and large envelope glycoproteins, respectively (de
Vries, et al., 1992; Faaberg and Plagemann, 1995). The PRRSV ORF 5 product was also
shown to encode a glycoprotein but the ORF 2 product could not be detected in purified
virions (Meulenberg, et al., 1995). In the present study, one of the SHFV large envelope
glycoproteins (p54) was mapped to ORF 7. Similar to the EAV, LDV, and PRRSV ORFs
5, the SHFV ORF 7 is the third ORF located from the 3 ' end of the viral genome.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

99

The ORFs 3 and 4 products of EAV, LDV, and PRRSV encode putative
glycoproteins. The PRRSV ORFs 3 and 4 products were reported as viral envelope
glycoproteins (van Nieuwstadt, et al., 1996). However, the corresponding gene products
have not been detected in EAV or LDV particles. Although the gene products o f the SHFV
ORFs 2a through 6 remain unidentified, it was recently reported that small stretches of amino
acid identity were found between some of these ORFs and ORFs from the other arteriviruses
(Godeny, et al., 1998). The SHFV ORFs 2a and 4 products share a conserved amino acid
sequence, -HPLG-, with the PRRSV ORF 2 product The conserved seven amino acid
sequence -FHPELFG- was found in the SHFV ORF 2b product as well as the PRRSV ORF
3 product Lastly, an -RWA- sequence was conserved in SHFV ORFs 3 and 6 and the
PRRSV ORF 4 products. Computer-aided sequence comparisons did not detect significant
sequence similarity between the ORF 5 product and any of the other SHFV proteins.
However, both the number and distribution of cysteine residues in the ORF S encoded
peptide was remarkably similar to those in the ORF 2b product Due to these sequence
homologies and the positioning of conserved cysteine residues in the arteriviral 3' ORF
products, it was proposed that the SHFV ORFs 2a through 6 were related to the EAV, LDV,
and PRRSV ORFs 2 through 4 products (Godeny, et al., 1998). Further, it was postulated
that the SHFV ORFs 4 through 6 might have been generated through a heterologous RNA
recombination event during which ORFs 2a, 2b and 3 were duplicated (Godeny, et al., 1998).
Further support for a recombination event can be found in the overlap regions of the 3'
ORFs. All but two o f the SHFV ORFs overlap their adjacent 5' ORFs (Smith, et al., 1997);
there is a noncoding gap of 42 nt between ORFs 3 and 4, and a 5 nt gap between ORFs 6 and
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7. These gaps suggest that the RNA encoding ORFs 4 through 6 may have been placed
between existing overlapping ORFs.
During replication, arteriviruses produce sets of sgRNAs which are nested and 3 ' co
terminal (reviewed in de Vries, et al., 1997 and Snijder and Meulenberg, 1998). The
sgRNAs each contain a 5' leader sequence which is joined to the body of the sgRNA by a
conserved junction sequence (de Vries, et al., 1997; Snijder and Spaan, 1995). The overall
SHFVjunction sequence is 5'-UCNUUAACC-3 ' in which only the residues at position 7 and
8 are strictly conserved. This junction sequence is similar to those found for the other
arteriviruses: 5'-UCAAC(U/C)-3' for EAV (den Boon, et al., 1996), 5'-U(A/G)(U/A)AACC3' for LDV (Godeny, et al., 1993; Kuo, et al., 1992), and 5'-GNUNAACC-3' for PRRSV
(Conzelmann, et al., 1993; Meulenberg, et al., 1993a). The 3' nucleotides of the LDV,
PRRSV, and EAV junction sequences are conserved as 5'-AAC(U/C)-3\ Indeed, this
sequence motif appeared in six of the eight SHFV junction sequences (Fig.4). Although the
conserved junction sequence of SHFV is similar to those of the other arteriviruses, it appears
to be longer and shows less nucleotide conservation. Unlike the other arteriviral junction
sequences which are rich in adenine and uridine (Snijder and Spaan, 1995), the SHFV
junction sequence is rich in uridine and cytidine residues.
Northern blot analysis of cytoplasmic RNAs from SHFV infected cells revealed that
six sgRNAs, estimated at 4.7,3.3,2.7,2.0,12 , and 0.65 kb in lengths, were produced during
virus replication (Godeny, et al., 1995; Zeng, et al., 1995). Because one sgRNA is produced
for each of the arteriviral 3' ORFs (Snijder and Spaan, 1995) and SHFV encodes nine 3'
ORFs, it was expected that SHFV should produce nine sgRNAs. However, the junction
sequence data suggests that SHFV produces eight sgRNAs during replication, in contrast
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with the other three arteriviruses which produce six to seven sgRNAs during replication
(Kuo, et al., 1992; Meulenberg, et al., 1993a; van Berio, et al., 1986). These SHFV sgRNAs
were numbered RNAs 2 ,3 ,4 ,5 , 6, 7, 8, and 9 and their sizes were predicted to be 5.049,
4.032, 3.454,2.827, 2.642,1.921,1.210, and 0.629 kb in length, respectively. Except for
RNAs 3 and 5, the lengths of the SHFV sgRNAs correspond to the estimated sizes of the
previously reported six sgRNAs (Godeny, et al., 1995; Zeng, et al., 1995). Interestingly, the
junction sequence amplicons from RNAs 3 and 5 were always lower in concentration than
those of the other six sgRNAs suggesting that these two RNAs are produced in low amounts
during viral replication and may, in fact, be synthesized at levels too low to be detected by
Northern blot hybridization. This could explain why these sgRNAs were previously
overlooked.
Since SHFV produces eight sgRNAs, it is presumed that at least eight of the nine
SHFV 3' ORFs are functional. ORF 2b was found to lack a unique junction sequence
suggesting that this gene may be silent. However, since icosahedral RNA viruses do not
usually encode silent genes, another possibility is that RNA 2 is polycistronic; both ORFs
2a and 2b may be translated from RNA 2. Although the coronaviruses are known to
synthesize polycistronic sgRNA (de Vries, et al., 1997, Cavanagh, et al., 1994, Siddell,
1995), SHFV is the first arterivirus presenting two ORFs on one sgRNA only. Since this
SHFV ORF 2a/ 2b phenomenon was reported (Godeny, et al., 1998), a second ORF (ORF
2a on EAV, LDV, and PRRSV and ORF 4a on SHFV) was identified which would make the
EAV, LDV and PRRSV RNAs 2 and the SHFV RNA 4 polycistonic (de Vries and Snijder,
personal communication). These new arterivirus ORFs encode a small (60 to 80 amino acids
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in length), hydrophobic protein similar to the coronavirus E protein (Cavanagh, et al., 1994;
Spaan, et al., 1988).
It was previously reported that SHFV encodes at least four structural proteins, plS,
p20, p42, and p54 (Godeny, et al., 1995). In the present study, the p42 and p54 glycoproteins
were shown to consist of at least four glycoproteins which comigrate. These glycoproteins
have peptide backbones ranging in mass between 28 and 30 kDa. These data suggests that
at least six structural proteins make up the SHF virion particle. One of the p54 glycoproteins
mapped to ORF 7 on the SHFV genome. This result was expected because of the high
number of potential N-linked glycosylation sites encoded by this ORF and the
hydrophobicity pattern of the ORF 7 product which was similar to those of the other
arteriviral GLproteins. Since there are nine 3' ORFs on the SHFV genome, the potential
exists for nine SHFV structural proteins. Until all of the SHFV 3' ORFs are expressed and
their products mapped to the genome it can not be determined if the additional three ORFs
encode nonstructural proteins, as yet unidentified structural proteins, or if the genes are
silent
Protein analysis studies indicated that the GLproteins of LDV, EAV, and PRRSV
exhibit a similar and rather unique structure, despite considerable amino acid divergence (de
Vries, et al., 1992; den Boon, et al., 1991b; Faaberg and Plagemann, 1995; Meulenberg, et
al., 1995). These GLproteins possess a potential signal peptide and three potential internal
transmembrane segments, although it is not known if this internal hydrophobic domain spans
the viral envelope one or three times. In the LDV GLprotein, an ectodomain of about 30
amino acids was predicted to project externally from the viral envelope after signal sequence
cleavage (Faaberg and Plagemann, 1995). This LDV ectodomain possesses three potential

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

103

N-linked glycosyladon sites. In contrast, an ectodomain of about 95 amino acids is proposed
for the EAV GLprotein. The EAV ectodomain contains a single polylactosaminoglycan side
chain (de Vries, et al., 1992; den Boon, et al., 1991b). Because the hydrophobicity pattern
for the SHFV ORF 7 peptide is consistent with those of the EAV, LDV, and PRRSV GL
proteins, it is presumed that it possesses a similar membrane topography. Indeed, the
predicted signal sequence cleavage site for the SHFV ORF 7 peptide is at amino acid 41. If
this signal cleavage site were used, an ectodomain o f approximately 100 amino acids would
remain before the transmembrane region. All of the eight potential N-linked glycosyladon
sites encoded in this protein are found within this ectodomain region.
The arteriviral GLproteins are important vital structural proteins; they are the major
envelope glycoproteins found on the surface of the viral particles. The EAV and LDV GL
proteins were found linked to the viral M proteins in intact virions (de Vries, et al., 1992;
Faaberg and Plagemann, 1995). This linkage was shown to result via disulfide bonds in
LDV (Faaberg and Plagemann, 1995). Further, the PRRSV GLprotein was shown to induce
apoptosis when expressed as a vaccinia virus recombinant (Suarez, et al., 1996a). However,
the relevance of this property for infection and pathogenesis is not known.
All known neutralizing antibodies produced against any of the arteriviruses react with
the respective viral GL protein (Balasuriya, et al., 1993; Coutelier and van Snick, 1988;
Deregt, et al., 1994; Glaser, et al., 1995; Harty, et al., 1987; Pirzadeh and Dea, 1997). Since
neutralizing activity can be mapped to the arterivirus GLprotein, it has been suggested that
this viral envelope glycoprotein may be involved in binding of the virus to the receptor on
the cell.

Neutralizing anti-EAV mAbs bind to the putative ectodomain, amino acids 19
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through 115, of the GL protein (Balasuriya, et ai., 1997). Further, neutralization escape
mutants of EAV contained mutations or deletions in the amino-terminal ectodomain of this
glycoprotein (Balasuriya, et al., 1997; Balasuriya, et al., 1995b; Glaser, et al., 1995). The
major neutralizing epitope of LDV was also mapped to the putative ectodomain of the GL
glycoprotein (Li, et al., 1998). The neutralisin g epitopes on the SHFV GLprotein have not
been mapped. In this report, four putative antigenic epitopes were identified on the SHFV
ORF 7 glycoprotein, GL, using mAbs. Because one of these mAbs also exhibits virus
neutralizing activity, it can be inferred that one of these four epitopes comprises a virus
neutralization site. It remains to be determined if any or all of these antigenic epitopes map
to the putative ectodomain on the SHFV GLglycoprotein.
Amino acid sequence comparisons of the capsid and membrane proteins have
suggested that LDV, PRRSV and SHFV are more similar to each other than they are to EAV
(Godeny, et al., 1995; Snijder and Meulenberg, 1998). The capsid protein of SHFV shows
little similarity to the other arteriviruses. This SHFV protein showed a 39%, 39% and 41%
sequence similarity with the capsid proteins of EAV, LDV and PRRSV, respectively
(Godeny, et al., 1995). Whereas the amino acid similarity between the capsid proteins of
EAV and LDV was 47%, EAV and PRRSV was 42%, and LDV and PRRSV was 57%. The
arteriviral membrane proteins are more conserved than the capsid proteins. The amino acid
sequence similarity between the M proteins of EAV and LDV was 44%, between EAV and
PRRSV was 47%, and LDV and PRRSV was 70%. The SHFV membrane protein exhibited
48% similarity with the EAV protein, 54% similarity with the LDV protein, and 57%
similarity with the PRRSV protein (Godeny, et al., 1995). The SHFV GLprotein shares 43%,
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53%, and 57% sequence similarity with the GL proteins of EAV, LDV, and PRRSV,
respectively. These GLprotein sequence comparisons further substantiate the phylogenetic
relationship between LDV, PRRSV, and SHFV.
Since the arteriviral GLglycoproteins are thought to project from the surface o f the
viral envelope it is expected that they would encounter a high degree of immunological
pressure. Therefore a reasonable amount of amino acid sequence divergence would be
expected to appear among different isolates of arteriviruses. Indeed, field isolates o f EAV
exhibited between 89.8% and 99.6% identity within the GLpeptide sequence (Balasuriya,
et al., 1995a; Glaser, et al., 1995). A study of different European and North American
isolates of PRRSV showed that the GLenvelope glycoprotein was the most heterologous
polypeptide of the viral structural proteins (Balasuriya, et al., 1995a; Mardassi, et al., 1995;
Suarez, et al., 1996b). Therefore, it was quite surprising that no differences were observed
in the SHFV GLamino acid sequence among the prototype isolate (a laboratory strain first
isolated in 1964 from an infected rhesus monkey) and two isolated from the 1989 New
Mexico outbreak, especially since one of the New Mexico isolates was isolated from a mouse
and not a monkey. This conservation of the SHFV GLpeptide sequence suggests that few
alterations in this glycoprotein are tolerated for virus survival. Additional isolates need to
be examined in order to substantiate this hypothesis because of the low number o f SHFV
isolates compared in this study,.
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5.

SUMMARY AND CONCLUSIONS
The 3' end of the genome from the prototype isolate of SHFV was successfully

cloned and sequenced. The SHFV genome contains nine 3' ORFs, which were identified as
ORFs 2a, 2b, 3, 4,5, 6, 7, 8, 9 moving from the 5' end to 3' end of the genome using
conventional nomenclature. Compared with the genomes of other arteriviruses, SHFV
contains three additional ORFs. The SHFV 3 ' end sequence contains the 76 nt 3' noncoding
region, all of the 3' ORFs and 1,590 nt of the SHFV ORF lb gene.
SHFV produces eight sgRNAs during replication, in contrast with the other three
arteriviruses, which produce six to seven sgRNAs during replication. These SHFV sgRNAs
were numbered as 2 ,3 ,4 , 5, 6, 7, 8, and 9. Their sizes were determined to be 5.049,4.032,
3.454, 2.827, 2.642, 1.921, 1.210, and 0.629 kb in length, respectively. The arteriviral
sgRNAs are composed of a 5' leader sequence which is joined to the body of the mRNA
through a conserved junction sequence. The overall SHFV junction sequence is 5'UCNUUAACC-3' in which only the residues at position 7 and 8 are strictly conserved. The
conserved j unction sequence of SHFV is similar to those of the other arteriviruses. However,
the SHFV junction sequence appears to be longer and shows less nucleotide conservation
than those of the other arteriviruses.
It was previously reported that the SHFV particle was made up of at least two
structural proteins, pi 5 and p20, and two structural glycoproteins, p54 and p42. In the
present study it was found that p42 and p54 are actually four glycoproteins which comigrate
by SDS-PAGE. These glycoproteins have peptide backbones ranging in mass between 28
and 30 kDa after digesting by endoglycosidase F. These peptides reacted with specific
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polyclonal antiserum against SHFV by Western blot analysis. Combining these data with
the previously reported number of proteins within the SHFV particle, the SHF virion particle
consists of at least six structural proteins.
Immunoprecipitation studies using the in vitro expressed SHFV ORF 7 product
proved that this gene encodes one of the SHFV large envelope glycoproteins, GL. This result
was expected because of the high number of potential N-linked glycosylation sites encoded
by this ORF and the hydrophobicity pattern of this gene product which was similar to those
of the other arteriviral GL proteins. Similar to the EAV, LDV and PRRSV ORFs 5, the
SHFV ORF 7 is the third ORF located from the 3' end of the viral genome.
Eight mAbs were produced by genetic immunizations of mice with the SHFV ORF
7 gene. These mAbs were used to delineate four antigenic epitopes on the SHFV ORF 7
glycoprotein. Because one of these mAbs also exhibits virus neutralizing activity, it can be
inferred that one of these four epitopes comprises a virus neutralization site.
The ORF 7 genes from two additional SHFV isolates were cloned, sequenced, and
compared to that of the prototype SHFV isolate. Surprisingly, no differences were observed
in SHFV Gl amino acid sequence among the prototype isolate and the two isolates from the
1989 New Mexico outbreak.
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